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Abstract 
Cardiovascular pre-participation screening in sport remains a controversial area.  The general 
consensus is that it should be available given the increased risk of sudden cardiac death with 
exercise, but debate exists to the format of this screening.  Part 1 of this thesis examines the 
incidence and epidemiology of death in young people to set the context; Part 2 evaluates the 
results of the Cardiac Assessment in Young Athletes (CAYA) programme in Scotland.   
 
Part 1 investigated a database of 41,049 deaths in those aged 0-35 years in Scotland from 
1986-2008.  Information such as location of death, whether a PM had taken place and cause 
of death was examined for all subjects with deaths categorised as those which occurred in-
hospital or out-of-hospital and by age category and sex.  Cardiac deaths (n=2084) were then 
investigated further. 
 
Analysis showed that the majority of deaths in young people in Scotland are due to accidents 
(27%), self-harm (16.2%) and cancers (11.8%).  Coronary artery disease is the largest 
contributor of cardiac deaths in young people in Scotland (30%) with the greatest number 
occurring out-of-hospital (55.3%). Only a relatively small number of deaths (0.9% of total) 
were due to conditions that would be identified and potentially prevented by a cardiac 
screening programme.   
 
Part 2: The CAYA study was based on the Italian Model of screening by personal and family 
history, physical examination and resting 12-lead ECG, with the addition of an 
echocardiogram for all participants. Data was available for 1713 subjects from the CAYA 
study from October 2009-December 2012.  Results showed a high incidence of hypertension 
in this young, athletic population, with a pilot study suggesting that this is likely to be 'white 
iii 
coat hypertension'. Screening with ECG identified 3 subjects with Wolff Parkinson-White 
syndrome and 1 with Long QT syndrome. Around 5% of subjects demonstrated left 
ventricular hypertrophy out with normal limits on echo (>13mm), but no structural 
abnormalities such as cardiomyopathy were diagnosed.  Use of the ECG in cardiac screening 
remains controversial but these results suggest that, although the ECG is not a useful 
diagnostic tool for identifying those with left ventricular hypertrophy, it has a high negative 
predictive value meaning it can identify those without pathology.   
 
In conclusion, these results do not support the inclusion of echocardiography as a tool in 
cardiovascular screening in Scotland.  The majority of cardiovascular deaths identified in this 
study were due to undiagnosed coronary heart disease which would not be identified by 
screening. Other causes of sudden cardiac death which may be identified by screening, such 
as familial arrhythmias and cardiomyopathies, are rare in Scotland. A screening service with 
ECG should be available to athletes and young people in Scotland but this should remain 
voluntary for those with symptoms or a positive family history.  Improved first aid education 
and provision of defibrillators at sporting facilities would perhaps help to reduce the number 
of fatalities that occur in young athletes.  
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Chapter 1 - Introduction 
The death of any young person is tragic, but the death of an athlete who is deemed to be at 
the peak of physical health is a larger shock and often receives a great deal of media interest. 
In 2012 several high profile sports stars suffered from fatal cardiac events including 
Norwegian swimmer Alexander Dale Oen, Italian footballer Piermario Morosini and a sudden 
death during the London Marathon.  In addition to this, in the UK there was added media 
attention following the cardiac arrest of Fabrice Muamba whilst playing for Bolton 
Wanderers. Whether the number of such deaths is increasing, or whether these are just 
being reported more frequently remains unknown, because there is a lack of an international 
database to record these deaths and the circumstances surrounding them. 
 
It has been identified that up to 80% of these deaths are due to cardiac causes1. This suggests 
that athletes may be put at an increased risk as a result of undiagnosed predisposing cardiac 
conditions, for example structural heart disease such as cardiomyopathies or familial 
arrhythmias such as long QT syndrome (LQTS). 
 
The consensus opinion is that some form of cardiovascular screening should be available to 
identify such problems; however controversy currently exists surrounding the efficacy of 
ways to identify these conditions.  In Europe, the gold standard protocol is the Italian Model 
which includes personal and family history questionnaire, physical examination (PE) and 
resting ECG2.  In America, the American Heart Association (AHA) guidelines rely on a 12-point 
personal and family history questionnaire and PE3. They have resisted the use of ECG on the 
basis of cost, doubts over the knowledge base of ECG morphology in athletes and fear of 
increasing anxiety in false positive results.   
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Until now the advice of the National Screening Committee (NSC) in the UK is that pre-
participation screening should not become a national programme for the general population, 
because of a lack of evidence of effectiveness of existing screening tests4, but should instead 
be targeted at those at high risk of cardiac complications with exercise. 
 
1.1. What is Sudden Cardiac Death (SCD)? 
Sudden cardiac death (SCD) is not a new phenomenon.  Greek mythology suggests that in 
490BC, Pheidippides suffered a SCD after running from Marathon into Athens to announce 
the Greek victory over its invaders. However an exact definition of SCD is hard to apply with 
only two thirds being witnessed5 6. 
 
The World Health Organisation (WHO) definition of sudden cardiac death includes 
instantaneous deaths and all deaths from cardiac cause occurring within 24 hours of an acute 
collapse7 and this definition has been used in many studies8 9 10;  however other studies have 
used a shorter cut off such as 1 hour11 12, 6 hours  or 12 hours13 14. The definition of SCD used 
influences the data generated and affects the proportion of natural deaths due to cardiac 
cause.  Zipes et al15 report this as being 13% of natural deaths when using a 1 hour cut off. 
This percentage will increase depending on the time cut off used as has been reported to be 
as high as 18.5% in a study using a 24 hour time period in The Netherlands16.   
 
Due to the way data is recorded in many countries including Scotland, and the fact that the 
time of symptom onset is not recorded on the death certificate, it is impossible to use these 
exact time cut offs.  Therefore, the definition which has been commonly used instead is ‘out-
of-hospital deaths’ (OOH deaths) which can be attributed to be sudden or unexpected death 
which occurs outside of hospital, within the emergency room or if subjects are pronounced 
dead on arrival to hospital17 18. The definition used has an impact on the figures recorded for 
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the incidence of deaths.  The incidence is also dependent on the study population with age, 
ethnicity and sex all being influential factors.  
 
Whether sudden death in sport is becoming increasingly frequent or is merely better 
reported remains an important question; are athletes really at greater risk than the general 
population?  A prospective study by Corrado et al2 aimed to answer that question by 
evaluating the incidence of sudden death in both the athletic population and the general 
population in Italy from 1979-1999. This study identified 300 cases of sudden death in 12-35 
year olds during the 21 year study period, giving an incidence of 1 death per 100, 000 person 
years.  Fifty five deaths occurred in athletes, with 245 occurring in the general population 
(p=0.002) which gave incidences of as 2.3 sudden death per 100,000 person years in athletes 
compared with 0.9 sudden deaths per 100,000 person years in the general population.  These 
results suggest that being an athlete, and therefore undertaking high levels of vigorous 
physical training, could be a risk factor for SCD. 
 
So, are athletes more ‘at risk’?  Evidence suggests exercise can act as a trigger for cardiac 
arrest15 19 20 but this can only happen if there is an underlying cardiac problem predisposing 
the athlete to an arrhythmia.  However, there are few prospective studies in this area 20 21 22 
with most being retrospective23 24 25 including newspaper articles and Google searches to 
identify the study population.  This highlights the need for a more reliable recording system 
of such deaths universally so that we can correctly identify how wide-scale the incidence for 
SCD is.  Often studies include deaths in athletes which do not occur during exercise and this 
may also affect the data23, as it is not possible to know if these are linked to sports 
participation. 
 
Table 1-1 shows papers which have examined sudden death in young populations. It 
demonstrates that the incidence of sudden death ranges from 0.3-0.6 per 100,000 in high 
school athletes to 13.2 deaths per 100,000 in army recruits.  Some of this variation can be 
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attributed to the way that data was collected and the age group monitored but it suggests 
that better recording of such deaths could lead to a uniform comparison between countries 
and athletes/non-athletes.   
 
Table 1-1: Studies that have investigated the incidence of sudden deaths in young 
populations 
Study Population Age Methodology/Study 
Design 
Incidence 
(person years) 
Maron (1998) High school 
athletes Minnesota 
13-19 years Retrospective cohort  0.5 per 100,000 
Corrado (2006) Competitive 
athletes, Italy 
12-35 years Mandatory Register for 
SCD 
3.6 per 100,000 
Eckhart (2004) Young Military 
recruits, USA 
18-35 years Autopsy based 13.2 per 100,000 
Behr et al 
(2007) 
White Caucasians, 
UK 
4-64 years SADS cases identified by 
Coroner 
1.34 per 100,000 
Vaartjes et al 
(2009) 
Young people, 
Netherlands 
1-40 years Death certificate out of 
hospital cardiac deaths 
1.62 per 100 000 
Shen et al 
(1995) 
Young adults, 
Minnesota  
20-40years Retrospective analysis of 
death certificates 
6.2 per 100,000 
Harmon et al 
(2011) 
National Collegiate 
Athletic 
Association 
(NCAA) Athletes 
17-24 years NCAA database, 
insurance company 
claims, media reports 
2.3 per 100,000 
Van Camp et al 
(1995) 
High school and 
college athletes 
12-19 years Prospective 10 year 
study of non-traumatic 
deaths  
0.3 per 100,000 
Maron et al 
(2009) 
1866 deaths in 
athletes  
15-39 years Retrospective analysis 
using specialist database 
and Google/Yahoo 
searches 
0.6 per 100,000 
Steinvil et al 
(2011) 
Deaths of 
competitive Israeli 
male athletes 
12-44 years Retrospective analysis of 
media sources 
2.6 per 100,000 
Holst et al 
(2010) 
 
Sports related 
SCD in Denmark 
12-35 years Retrospective analysis of 
death certificates and 
public media reports 
1.21 per 100,000 
SCD-Sudden cardiac death, SADS-Sudden arrhythmic death syndrome 
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1.2. Causes of SCD 
Cardiac deaths in older adults (>35years) are generally accepted as being largely attributed to 
coronary heart disease (CHD). However the cause of  death in younger people (1-35 years) 
are harder to identify.  This is made more difficult due to the fact 25-40% of deaths in those 
aged 1-40 years are described as having a 'negative autopsy' where there is a lack of 
evidence to assign a definite known cause of death26.  Here, undiagnosed arrhythmias are 
often thought to be responsible with the heart appearing structurally normal at post mortem 
(PM) examination although this is difficult to prove without a diagnosis prior to death.  
 
 
SCD in the young are mainly due to structural abnormalities, such as coronary artery disease 
(CAD) and inherited cardiomyopathies, or familial arrhythmias such as long QT syndrome 
(LQTS) and Brugada syndrome. There are also a number of other causes of deaths which have 
been reported as potentially having a cardiac origin. These have been classed as 'class B' 
cardiac deaths as post mortem is negative and include unexplained car accidents and 
unexplained drowning and submersion in natural water27.  This is due to the fact that the 
drowning or other incident such as epileptic seizure may have been caused by a primary 
myocardial disorder.  
 
Although in many cases of SCD, the underlying cause is structural or due to an electrical 
abnormality, the final event which leads to cardiac arrest is always an arrhythmia such as 
ventricular fibrillation (VF) or ventricular tachycardia (VT).  There are a number of 
mechanisms that result in arrhythmia: 1) automaticity 2) triggered activity - delayed  after-
depolarisation  or early after-depolarisation and 3) re-entry28. In electrical abnormalities 
ventricular arrhythmia may be caused by triggered activity whereas structural abnormalities 
such as CAD and cardiomyopathies are commonly caused by re-entry arrhythmia as a result 
of scarring, tissue damage and fibrosis.  
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1.2.1. Cardiomyopathies 
The term 'cardiomyopathy' covers a number of conditions, broadly categorised as heart 
muscle disease.  There are 3 main types of cardiomyopathy that affect the young: 
hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and arrhythmogenic 
right ventricular cardiomyopathy (ARVC).   
 
1.2.1.1. Hypertrophic Cardiomyopathy (HCM) 
Hypertrophic cardiomyopathy is defined as heart muscle disease characterised by 
unexplained hypertrophy of the left (and sometimes the right) ventricle. This hypertrophy is 
asymmetric and affects the inter-ventricular septum more than the left ventricular free wall. 
HCM is an inherited autosomal dominant disease, most common in males of black origin. 
Histologically it is characterised by myocyte disarray which predisposes the subject to cardiac 
arrhythmias particularly ventricular fibrillation (VF) and ventricular tachycardia (VT).   
Patients can complain of chest pain, palpitation and blackouts with diagnosis being through 
ECG, echo and MRI.  Surgical treatments include ablation, myectomy or coronary artery 
injection and, in patients at high risk of SCD, fitting of an implantable cardioverter 
defibrillator (ICD).  
 
1.2.1.2. Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) 
Arrhythmogenic right ventricular cardiomyopathy is reported as one of the most common 
causes of SCD in the young, particularly in Italy2. The exact prevalence of ARVC is unknown 
but is estimated at 1 in 10,000, meaning there are approximately 5000 affected individuals in 
the UK29.  The condition is hereditary and has been reported to affect males and females 
equally.    
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ARVC is characterised by a progressive replacement of normal right ventricular muscle cells 
by fibrous tissue and fat which can lead to ventricular arrhythmia and heart failure. 
Regrettably, in many cases SCD is the first manifestation of the disease with diagnosis made 
at post mortem but live diagnosis can be made using ECG, echo, MRI and electro-
physiological studies. Treatment includes lifestyle modification to reduce the risks of SCD, 
beta-blockers, anti-arrhythmic drugs, surgical ablation or implantation of an ICD.  
 
1.2.1.3. Dilated Cardiomyopathy (DCM) 
Dilated cardiomyopathy causes the ventricles to become enlarged causing poor contraction 
which can lead to heart failure. It occurs when the myocardium becomes damaged which can 
be familial or can be due to existing cardiac disease, toxins or infection. It causes shortness of 
breath, ankle swelling and palpitations and would be diagnosed using ECG, echo and possibly 
an exercise test.  Treatments include diuretics, ACE inhibitors, implantation of an ICD or heart 
transplantation. 
 
1.2.2. Familial Arrhythmias  
Familial arrhythmias are a group of conditions that are characterised by inherited electrical 
abnormalities in the heart. These abnormalities cause irregular heart rhythms which may be 
the cause of death, and may be the cause of SCD particularly where there is no structural 
abnormality found at post mortem30.  Cardiac arrhythmia may be the first sign of any cardiac 
disease and may prove fatal.  
 
1.2.2.1. Long QT Syndrome (LQTS) 
Long QT syndrome is a disease that mainly effects children and young adults and is 
recognised as the leading arrhythmic cause of death in this population31. It is now estimated 
to affect 1 in 2000 people32. LQTS is caused by one of several gene mutations which prolong 
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the ventricular action potential causing the QT interval of the ECG to be lengthened 
(>440ms). The cause of death is polymorphic ventricular tachycardia ("torsades des pointes") 
or VF. Exercise is a recognised trigger for arrhythmia in some genotypes (e.g. LQT1). Patients 
with LQTS are advised to avoid drugs which prolong the QT interval such as anti-histamines, 
and may be advised to avoid competitive sports. Treatments include beta blockers and high 
risk patients are fitted with an ICD33. 
 
1.2.2.2. Short QT Syndrome (SQTS) 
Short QT syndrome is uncommon and occurs when the ventricle takes a shorter time than 
normal to repolarise so that the QT interval is <300ms.  This occurs due to increased activity 
of potassium channels causing a shortening of the action-potential phase and makes the 
subject prone to ventricular arrhythmias.  Treatment is with anti-arrhythmic drugs and ICD34. 
  
1.2.2.3. Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) 
Catecholaminergic polymorphic ventricular tachycardia is an inherited arrhythmogenic 
disorder which is estimated to affect 1 in 10,000 people worldwide mainly in adolescent 
males. It occurs when there are increased levels of calcium inside the heart cells which leads 
to arrhythmia. Diagnosis is made using exercise testing as it is characterised by ventricular 
tachycardia (VT) on exercise.  Treatment is with beta blockers and ICD implantation30.   
 
1.2.2.4. Brugada Syndrome 
Brugada syndrome is characterised by a distinctive ECG pattern including right bundle branch 
block (RBBB) and ST segment elevation.  This can lead to ventricular fibrillation (VF) with 
symptoms including blackouts and palpitations.  It is caused by a mutation in the sodium 
channels and is most common in South East Asia.  Death due to Brugada syndrome is not 
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thought to be associated with exercise and occurs more commonly during sleep30.  
Treatment requires implantation of an ICD. 
 
1.2.3. Other Conditions  
1.2.3.1. Coronary Heart Disease (CHD) 
The commonest cause of cardiac death in the Western World in all ages is acute myocardial 
infarction (MI) which is caused by acute thrombotic occlusion of a coronary artery at the site 
of an atherosclerotic plaque35.  Statistics from the British Heart Foundation suggest that in 
2008, as many as 35 people a day died from CHD in the UK36. Although the numbers of 
deaths due to MI have reduced in recent years due to surgery and new therapeutic 
interventions, poor diet, smoking and an inactive lifestyle all contribute to make CHD a major 
problem, particularly in Scotland. Age is also seen as an important risk factor but CHD does 
manifest itself in younger people who can remain asymptomatic for many years. In 2008, 
CHD was responsible for 25.4% of deaths in those under 75 years in Scotland compared with 
15.0% in England and 14.5% in Wales36. Coronary heart disease cannot always be diagnosed 
using ECG and echocardiography alone (unless there has been a prior event) and instead 
would be require the use of exercise testing and angiography.   
 
1.2.3.2. Wolff-Parkinson White (WPW) Syndrome 
In 1930, Wolff, Parkinson and White described a series of patients who presented with a 
bundle branch pattern on ECG, a short PR interval and evidence of tachycardia37.  This pre-
excitation pattern is caused by an additional electrical connection (accessory pathway) 
between the atria and ventricles thus shortening the PR interval and predisposing the patient 
to arrhythmia.  It is estimated that WPW syndrome occurs in approximately 1 in 1000 
athletes38.  Risk of sudden death occurs if the pathway has a short refractory period and the 
onset of atrial fibrillation (AF) can lead to VF. It is detected using ECG, with palpitation being 
the main symptom.   
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Table 1-2 details the cardiac conditions that commonly lead to SCD and details how these 
conditions can be identified.  None of the conditions can be identified using physical 
examination (PE) and although family history can be useful; this is normally in symptomatic 
subjects.  Table 1-2 suggests the ECG as the most useful diagnostic tool in identifying both 
structural and electrical abnormalities with further tests often required before a diagnosis is 
made.  
 
Table 1-2: Conditions that can pre-dispose to sudden cardiac death with potential 
diagnostic tools 
Condition Family 
History 
Symptoms PE ECG Echocardiogram Other 
Long QT 
Syndrome 
    
 
 24 hour holter 
monitor 
Ajmaline 
Provocation 
Short QT 
Syndrome 
    
 
 24 hour holter 
monitor 
CPVT     
 
 Exercise Test 
Brugada 
Syndrome 
    
 
 Ajmaline 
Provocation 
Hypertrophic 
Cardiomyopathy 
    
 
 
 
Exercise Test 
CMRI 
ARVC     
 
 
 
CMRI 
EP studies 
Dilated 
Cardiomyopathy 
    
 
 
 
Exercise Test 
Wolff-Parkinson 
White Syndrome 
    
 
 EP Studies 
Coronary Heart 
Disease 
     
(if previous MI) 
Exercise Test 
Angiography 
 
(CPVT= catecholaminergic polymorphic ventricular tachycardia; ARVC= 
arrhythmogenic right ventricular cardiomyopathy; PE= physical examination; 
CMRI= cardiac magnetic resonance imaging; EP=electro-physiological) 
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1.3. Sex and Gender Differences  
SCD has been found to be more common in male athletes than females with studies showing 
up to a 9:1 ratio2 39. Perhaps this is due to the larger male participation rates and the types 
and intensity of sports undertaken, or maybe there is an underling hormonal cause? 
 
Studies agree that there appears to be a genetic/ethnicity bias towards SCD with black 
athletes being more at risk of SCD than Caucasian athletes, however there is disparity across 
studies as to the incidence of this.  In America, most SCD are due to HCM with these being 
more common in black athletes whereas arrhythmias were found to be more common in 
non-black athletes40.  In Italy, the leading cause of SCD is ARVC2; however this is not 
replicated anywhere else in the world.  This suggests that there may be a genetic 
predisposition to certain conditions which are attributable to the geographic distribution or 
ethnicity.  
 
 
1.4. Cardiovascular Adaptations to Exercise 
It is well documented that the heart undergoes a series of changes in response to exercise or 
physical training41 42.  These physiological adaptations induced by chronic exercise increase 
both preload and afterload on the heart and lead to a form of cardiac remodelling. This 
comprises of ventricular hypertrophy, an increase in cardiac chamber size and enhanced 
diastolic ventricular filling, which provides an increase in stroke volume (SV)41.  These 
cardiovascular changes are produced by a complex interaction of central and peripheral 
mechanisms, which operate at structural, biochemical and metabolic levels42.   
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The ‘Morganroth hypothesis’ was first presented by Joel Morganroth and colleagues in 1975 
to suggest the theory that different types of exercise training elicit different structural 
changes within the heart43. This theory proposed that endurance training elicits eccentric 
forms of hypertrophy characterised by increased LV cavity size and LV mass.  Strength 
training elicits concentric hypertrophy including increased wall thickness but no alterations in 
cavity size. However, this theory remains controversial.  
 
The 26th Bethesda Conference defined endurance or dynamic sports as those that involve 
“changes in muscle length and joint movement with rhythmic contractions which develop a 
relatively small intramuscular force”, whilst strength or static training was referred to as 
activities that “develop relatively large intramuscular forces with little or no change in muscle 
length or joint movement44. However, most modern sports require a combination of both 
strength and endurance training meaning athletes are exposed to both static and dynamic 
demands. 
 
Dynamic exercise requires large muscle mass use and causes a marked increase in oxygen 
consumption generating a volume overload on the ventricle.  Therefore, dynamic sports 
result in larger absolute LV mass and chamber size45. These adaptations of the athlete’s heart 
are of major importance in the maximal oxygen uptake (VO2max) improvement that is 
described46. During progressive dynamic exercise, oxygen uptake increases from the resting 
value until maximal VO2max is achieved. During this exercise, both heart rate (HR) and SV 
increase causing an increase in cardiac output. The increase in SV is achieved by both an 
increase in end diastolic volume and a decrease in end systolic volume. By contrast, static 
exercise induces a small increase in VO2max, HR and cardiac output (CO) and no change in 
SV46.  These adaptations to static exercise generate an increase in LV mass without an 
increase in chamber size45. 
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Although exercise is well documented to be able to lower blood pressure in hypertensive 
patients47 and reduce cardiovascular risk, hypertension or high blood pressure is not an 
uncommon finding in athletes due to the increased size of the left ventricle48.   
 
1.5. Athlete's Heart vs Hypertrophic Cardiomyopathy 
Around half of highly trained athletes will demonstrate some form of cardiac remodelling49.  
These changes are more evident in the left ventricle (LV) which can show cavity enlargement, 
and increments in wall thickness.  The traditional physiological adaptation seen following a 
period of exercise is left ventricular hypertrophy (LVH), which can be eccentric or concentric 
in nature. Eccentric changes are normally associated with endurance training due to the 
volume load on the left ventricle whereas concentric changes are related to power training 
due to the pressure load45 50.  LVH is affected by sport, training intensity and duration but is 
also influenced by intrinsic factors such as age, sex, ethnicity and BSA. 
 
These physiological cardiac adaptations which occur following a period of high intensity 
exercise training are acknowledged and referred to as 'athlete's heart'. However, these 
changes can mimic those of hypertrophic cardiomyopathy (HCM), and mis-diagnosis would 
lead to the athlete being strongly advised against participating in competitive sport. This has 
led to a so-called 'grey area' in the literature identified in Figure 1-149. 
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GREY AREA 
 
 
Figure 1-1: The so-called 'grey area' described by Maron between physiological 
athlete's heart and pathological hypertrophic cardiomyopathy
49
 
                                                     
Research questions whether these changes are solely physiological due to training, or 
whether they may be due to underlying pathological causes. In order to measure this, an 
echocardiogram is necessary to assess levels of hypertrophy on the left ventricular posterior 
wall thickness (LVPWd) and the inter-ventricular septal diameter (IVSd) as well as assessing 
the size of the left ventricular cavity.  The physiological changes associated with athletes 
heart can be reversed following a period of de-training.  
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In addition to changes in wall thickness, the LV cavity can also be enlarged in athletes.  This 
enlargement can be mistaken for dilated cardiomyopathy and so it is important to recognise 
the upper limits of normal.  It is also recognised that cavity enlargement can exist without an 
increase in wall thickness due to the remodelling.  Reference values have been published for 
LV cavity size and this has been suggested as the most important discriminator between 
physiological LVH and pathological disease such as HCM51.  
 
 
As discussed, different sports place different demands upon the body, which have been 
reported to cause variation in the degree of hypertrophy demonstrated.  Most athletes in 
modern sport combine aerobic training with strength training which makes research difficult  
but ultra-endurance sports such as cycling, rowing and skiing have been shown to elicit the 
greatest increases in LVPWd measures52.  
 
                                                                                                                          
Normal limits of physiological LVH have been discussed in the literature42 53 and upper limits 
of normal are generally accepted as 13mm with measurements higher than this restricted to 
athletes such as rowers and cyclists53 . Subjects with LV wall measurements greater than 
13mm, should undergo further tests to rule out any pathology.   
 
 
A study was conducted on Scottish footballers to try to establish the degree of LVH found in 
this population54.  Footballers were compared with age matched controls and were found to 
have significantly greater left ventricular posterior wall thickness (9.2 v 8.5mm) and septal 
thickness (10.4 v 9.1mm). Only 17 footballers (12.1%) had a septal or wall thickness greater 
than 12mm. This research agrees with previous work53 that footballers generally fall within 
normal limits for LV measurements.   This suggests that perhaps footballers as a group are 
not as aerobically fit as athletes who participate in sports such as cycling and rowing.  
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1.6. Hypertension in Athletes  
Regular exercise is associated with decreased blood pressure, but elevated BP has been 
found to be the most common abnormality found during athletic pre-participation 
screening48. Whelton et al showed cardiorespiratory fitness to be inversely related to BP55.   
 
A BP greater than 140/90mmHg is considered as 'hypertension' in adults (those greater than 
18 years)56.  In those under 18, hypertension is defined as an average BP greater than or 
equal to the 95th percentile for gender, age and height57.  Task Force 5 from the 36th 
Bethesda Conference accept that young people who plan to participate in sport should have 
their BP routinely checked.  It states that athletes with high readings should have ‘additional 
recordings outside the office’ to exclude elevated anxiety readings or ‘white coat 
hypertension’ readings58.   
 
 
The National Institute of Clinical Evidence (NICE) has stated that white coat hypertension 
may exist in up to 25% of patients56.  There is sparse longitudinal data to suggest that young 
people with ‘pre-hypertension’ will develop hypertension in later life. The prevalence of 
hypertension in the physically active has been shown to be approximately 50% lower than 
that of the general population (Lehmann et al 1990).   
 
Kouidi et al59 conducted a study on 410 footballers, and found 10% (41 athletes) had blood 
pressure recordings above accepted normal limits after 2 or more measurements.  Following 
ambulatory 24hour monitoring, only 2 athletes had BP >140 or 90mmHg.  Another study did 
show that 80% of young athletes identified as having a BP greater than 142/92mmHg at pre-
participation screening developed chronically elevated BP after 1 year60.   
 
 
No clear correlations have been found between hypertension and SCD in young athletes61. 
However, a link does exist between hypertension and LVH though it is not apparent if this is a 
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cause and effect relationship. Isolated systolic BP has been shown to be associated with 
athlete's heart based on the mechanism of high resting SV and CO, and low HR with a wide 
pulse pressure62.  
 
 
Reims et al63 have suggested that one-off BP measurements are higher than ambulatory BP 
(ABP) measurements.  A study of footballers in Norway revealed a significant relationship 
between high BP, LV mass and HR64. A further study by Berge et al65 aimed to investigate the 
incidence of high ABP in male professional footballers in Norway.  Based on BP recordings 
carried out during routine pre-participation screening in 2008, a case control study recorded 
ABP from October 2010 to February 2011.  Players (mean age=28.3 years) with untreated 
high BP (n=28) were compared with age/ethnicity matched control with optimal BP (n=26). A 
weak but significant correlation (r=0.21, p<0.01) was found between screening BP and mean 
arterial pressure.  Of the 26 cases, 58% were found to have sustained hypertension with 42% 
having white coat hypertension.  In the control group, only 65% were found to be truly 
normotensive while the remaining 35% has masked hypertension.  The hypertension in this 
study would only be classed as 'pre-hypertension' according to our study and current 
guidelines with a mean ABP of 138/82.   
 
1.7.  The Adolescent Athlete 
The majority of studies in this area have been conducted in adults, with few in adolescents. 
Studies have shown66 67 that adolescent athletes display a form of LVH, with a greater IVSd 
and LVPWd than control subjects, but that these values still fall within normal limits.  
Questions remain regarding at what age the heart is fully developed in terms of size and 
structure.  Corrado et al68 suggest that screening children less than 12 years old reduces the 
sensitivity of the tests with most conditions including HCM and DCM not manifesting 
themselves until adolescence.  American and European guidelines suggest that screening 
should begin between 12 and 14 years old and that it should be repeated every 2 years.  In 
Italy, screening is mandatory for athletes aged 12-35 years2. 
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Young athletes, particularly footballers tend to have similar training patterns but variation 
exists in body size and biological maturation69. Skeletal age has been shown to be a better 
predictor of athletic performance than chronological age suggesting it is this instead of age 
that should indicate when athletes should be screened.  Fat free mass has been shown to be 
a strong determinant of left ventricular mass but Daniels et al70 argue lean body mass to be a 
better predictor.  This study did not find an independent relationship between sexual 
maturity and left ventricular mass suggesting it manifests itself through body size70.   
 
1.8. Implications for Screening 
Fabrice Muamba, who suffered a cardiac arrest while playing football for Bolton Wanderers 
in March 2012, had reportedly been screened 4 times71. This does not support the argument 
for cardiovascular screening and suggests that it may not be an effective way to prevent a 
cardiac event if an underlying condition exists.   
 
The National Screening Committee in the UK established a set of criteria (Table 1-3) to assess 
the effectiveness and appropriateness of any potential screening programme72.  These 
criteria state that the targeted condition should be a significant public health issue, which 
can be targeted by a safe and effective and inexpensive treatment strategy.  
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Table 1-3: National Screening Committee Criteria for assessing effectiveness of a 
screening programme
72
 
1. The condition should be an important health problem 
2. The epidemiology and natural history of the condition should be adequately understood 
and there should be a detectable risk factor, disease marker or latent period 
3. There should be a simple, safe and precise validated screening test 
4. The test should be acceptable to the population 
5. There should be an effective treatment or intervention for patients identified through early 
detection, with evidence of early treatment leading to better outcomes than late treatment 
6. There should be evidence that the screening programme is effective in reducing mortality 
or morbidity 
7. The benefit from the screening programme should outweigh the physical and psychological 
harm (caused by the test, diagnostic procedure and treatment) 
8. The opportunity cost of the programme (including testing, diagnosis and treatment, 
administration, training and quality assurance) should be economically balanced in relation to 
expenditure on medical care as a whole (that is, value for money) 
 
 
In the United States, this has been modified by the US Preventive Services Task Force 
suggesting such a programme must improve specific health outcomes such as mortality, 
quality of life or pain73.  The main issue that is argued by the UK's National Screening 
Committee (NSC) is that cardiovascular screening of athletes does not 'fit' the above criteria. 
However, it is not designed to screen for only one condition.  These criteria suggest that 
cardiovascular screening would need to reduce the incidence of SCD to be worthwhile, and 
there have been no randomised control trials conducted to show this.  Instead, a 
comprehensive cardiovascular assessment is able to detect a number of different conditions, 
some of which are not life threatening, but will be a long term burden to both patient and 
NHS.  There are also ethical considerations involved with making screening mandatory, which 
is especially problematic in younger people.  
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The lack of a national register of SCD in the UK makes it hard to quantify the true incidence of 
this problem in the general population and also the numbers of deaths in athletes or those 
who die during or following exercise.  One study74 attempted to confirm the aetiology of SCD 
in athletes in the UK by examining 118 cases of SD in people participating in sport between 
January 1996 and July 2008.  All these cases had been referred to the Cardiac Risk in the 
Young (CRY) Centre for Cardiac Pathology at the Royal Brompton Hospital in London by local 
coroners and pathologists for further investigation.  Pathological analysis of the heart 
included measurements of left and right ventricular wall thickness and internal cavity 
dimensions, while histological investigation for any myocardial fibrosis or myocyte disarray 
was also carried out.  The coronary arteries were also studied.  Abnormal cardiac pathology 
was identified in 91 cases (77%) with the remaining 23% having morphologically normal 
hearts.  Left ventricular hypertrophy was discovered in 49 cases (42%) of athletes suggesting 
possible HCM; however only 13 out of 49 cases (27%) displayed associated myocyte disarray 
on histology which would confirm the presence of HCM.  Arrhythmogenic right ventricular 
hypertrophy was discovered in 16 subjects (14%) with evidence of biventricular involvement 
in 50% cases.  Coronary artery pathology was identified in 9% (11 cases).  Somewhat 
surprisingly, 96% of cases in this study were Caucasian which may be due to the population in 
the UK as other countries (USA) have found SCD and in particular those due to HCM are more 
prevalent in those with African-American origin. The number of morphologically normal 
hearts in this study (23%) is considerably higher than in previous studies, but we must look at 
this with caution as these figures were prior to introduction of pre-participation screening 
which may potentially have identified some electrical abnormalities in these cases. 
An American Heart Association (AHA) Scientific Statement3 advised the screening of children 
aged 12-18 years with an 8 point health questionnaire and a four point clinical examination.  
However, Wilson et al75 concluded from their study that “family history and personal 
symptom questionnaires alone are inadequate to identify people with disease associated 
with sudden cardiac death”.  This suggests further tests are required in addition to the 
questionnaire and physical examination to make the screening process more reliable.  The 
Lausanne Recommendations (2004) led to a common world screening protocol for Olympic 
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sports based on a personal and family history questionnaire, physical examination and 12-
lead ECG76.   
 
 
The concept that cardiovascular screening can significantly reduce SCD in athletes is largely 
based on information from the Veneto Region of Italy2.  This study suggests an 89% reduction 
in cases of SCD from 3.6 deaths per 100,000 person years before screening (1979 to 1982) to 
0.4 deaths per 100,000 person-years at the end after the introduction of mandatory 
screening.  However, these results have not been replicated in similar studies25, calling into 
question the general application to different populations. Some rationale for the significant 
reduction in SCD comes when we further evaluate the pre-screening data.  This data only 
encompassed deaths from the 2 years prior to the introduction of screening.  The number of 
deaths during these years was high and it could be that this caused a misrepresentation of 
the scale of the problem.  The high numbers could also have been the trigger for the 
introduction of mandatory screening.   
 
 
The only other European country which has introduced mandatory screening is Israel.  A 
study was carried out in Israel to evaluate whether the Italian data could be replicated in a 
different population25.  This study, which included an exercise test in addition to the Italian 
model, found no difference in the incidence of SCD before and after the implementation of a 
mandatory screening programme (1997).  Instead it found the average incidence of SCD to 
increase from 2.54 deaths to 2.66 deaths per 100,000 person years25.  So, how did these 
results differ so greatly from the Italian data? 
 
 
The positive results found in Italy could be due to an unusually high number of deaths in the 
years preceding the screening, with Israel using a 12 year pre-screening period which could 
have eliminated annual variation.  However, Italy used a National Register to calculate the 
number of deaths in preceding years whereas Israel relied on newspaper and media reports.  
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In both studies the number of competitive athletes was difficult to quantify. Israel 
extrapolated their data to allow for growth in the population, but there was no discussion of 
this in the Italian paper.  It is very difficult to generalise the Italian data as the population was 
mainly composed of white males and the lead cause of death was ARVC which has not been 
seen in any other studies and suggests this condition is more prevalent in the Veneto region 
of Italy. The death rate in Italy after implementing screening (0.43 deaths per 100,000 person 
years)2 is similar to that of the USA (0.5 deaths per 100,000 person years)77 who do not have 
a mandatory programme so perhaps SCD is more common in Italy? Potentially it may also be 
related to the high prevalence of ARVC which can be detected using ECG screening. 
  
 
1.9. The Cost of Screening 
 
Elston & Stein78  attempted to quantify the impact of establishing a similar screening 
programme to Italy in the UK for athletes aged 12-35 years.  By using the data from Italy, it 
was calculated that 38,151 athletes would need to be screened to prevent 1 SCD.  This 
suggests that if screening had a 100% uptake, 1.5 million athletes in the UK would be 
screened, with 140,000 being referred for further investigations such as echocardiography 
and exercise testing and with 31,522 being disqualified from sport.  This suggests that to 
prevent 1 SCD, 800 athletes would have to be disqualified.  This would incur a great deal of 
unnecessary anxiety placed on young athletes due to false positive results. While in some 
countries screening is mandatory, it is voluntary in others including the UK.  This leads to 
questions about consent and whether this is something that an athlete wants to undertake.  
A recent study in Switzerland79 surveyed 1047 athletes and only 47% expressed an interest in 
undergoing screening. Eighty percent of these athletes were symptomatic or had concerns 
leading to a selection bias in the research.  There are also questions to be answered over the 
ethics of offering screening to those involved in sport alone and what we class as an 'athlete'.  
There is also a possibility that by screening all involved in sport, we are creating a new 
vulnerable population who may be affected by the outcomes of positive tests.   
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1.10. Use of the ECG in Screening 
As well as significant debate regarding the implementation of cardiac screening as 
mandatory, controversy also exists in what format this screening process should take and the 
inclusion or exclusion of the electrocardiogram (ECG).  American experts acknowledge the 
benefits of ECG for diagnosing a breadth of potentially fatal cardiac disorders3 however they 
also question the implications of a high number of false positive results and needless further 
tests and potential disqualification. Their European counterparts suggest this is not the case 
and that screening should always include an ECG.   
 
In an athletic population the ECG can suggest evidence of both structural and electrical 
remodelling of the heart as a result of intense physical training.  Therefore, the ECG pattern 
in an athlete often looks abnormal, particularly in black athletes and it is this that the 
Americans worry will cause false positive findings.   Pelliccia et al38 reported that up to 60% of 
athletes present with abnormal ECG changes including sinus bradycardia, sinus arrhythmia, 
1st degree atrio-ventricular (AV) block, early repolarisation, incomplete right bundle branch 
block (IRBBB) and high voltage criteria.  Increased vagal tone in athletes often elicits a lower 
resting heart rate (HR) with more HR variability.  Sinus bradycardia is thought to be present in 
around 80% of trained athletes80 but this disappears on exercise. This low HR can also affect 
the corrected QT interval (QTc) as Bazett's formula has been known to be unreliable at low 
HR's.  
 
Early repolarisation has recently been suggested as a potential marker for risk of sudden 
cardiac death81. This phenomenon which describes J point elevation (or notching of the QRS 
terminal) is reportedly commonly found in young, physically active men. Early repolarisation 
can be misinterpreted by the computer as pericarditis or a myocardial infarction82 and high 
voltage criteria can be suggestive of structural abnormalities, both of which are more 
common in black athletes. This highlights the necessity of an experienced cardiologist to 
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oversee the results.    Other common ECG changes found in athletes include incomplete and 
complete right bundle branch block (RBBB) which has been postulated to be a reflection of 
right ventricular adaptations following exercise (Table 1-4)82. 
 
Table 1-4: Normal ECG findings associated with an athletic population with the 
abnormal values in this population 
Sinus bradycardia Up to 80% 
Sinus arrhythmia  Up to 55% 
Ectopic atrial rhythm  Unknown 
Junctional escape rhythm  8% 
1st° AV block  4.5-7% 
Mobitz type I (Wenckeback) 2nd ° AV block Unknown 
Incomplete RBBB 12-32% 
Voltage criteria for LVH 45% males, 10% females 
Early repolarisation Up to 45% (higher in black athletes) 
Complex ST segment elevation with T wave 
inversion 2-3% (13% in black athletes) 
(AV-atrioventricular, RBBB-right bundle branch block, LVH-left ventricular 
hypertrophy) 
 
There are also a number of abnormalities we can expect to see on an athlete's ECG which are 
not considered 'normal' and are unrelated to athletic training.  These may suggest an 
underlying pathology and would require further assessment (see Table 1-5). 
 
ECG abnormalities had been the subject of much debate and controversy before these 
guidelines, the Seattle Criteria (Table 1-4 and 1-5), were drawn up82 83.  These criteria are a 
refinement of previous ESC guidelines which aim to further reduce the false positive rate of 
the ECG in an athletic population.  The main difference in the new criteria is the lengthening 
of the abnormal QT interval. Previously, the QTc was thought to be abnormal at 440ms but 
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recent studies have increased this to 470ms (480ms in females). Previous QT cut offs have 
been derived from a non-athletic population and debate exists as to how accurate Bazett's 
formula is in calculating the QTc at low heart rates, which are common in an athletic 
population. The predictive value of the QTc in detection of LQTS is >500ms which exceeds the 
new criteria. 
   
Table 1-5: The Seattle Criteria for Abnormal ECG findings in athletes which would 
suggest further investigation
83
 
Abnormal Finding Definition 
T wave inversion >1mm in 2 or more leads 
ST-segment depression >0.5mm in 2 or more leads 
Pathologic Q waves >3mm or >40ms in duration in 2 or more leads 
Complete LBBB 
QRS >120ms, predominantly negative QRS 
complex in V1 
IV conduction delay Any QRS duration >140ms 
Left axis deviation -30 to -90 
Left atrial enlargement 
Prolonged P wave duration of >120ms in leads I 
or II with negative portion of P wave>1mm and 
>40ms in V1 
Right ventricular hypertrophy pattern 
R-V1+S-V5>10.5mm and right axis deviation 
>120 
Ventricular pre-excitation 
PR interval <120ms with delta wave and wide 
QRS (>120ms) 
Long QT interval 
QTc >470ms (male)/ QTc > 480ms (female) 
QTc > 500ms (marked QT prolongation) 
Short QT interval QTc <320ms 
Brugada-like ECG pattern 
High take off and down-sloping ST segment 
elevation followed by negative T wave in 2 leads 
(V1-V3) 
Profound sinus bradycardia <30bpm or sinus pauses 
Atrial tachyarrhythmias 
Supraventricular tachycardia, atrial fibrillation, 
atrial flutter 
Premature ventricular contractions 
>2 premature ventricular contractions per 10sec 
tracing 
Ventricular arrhythmias 
Couplets, triplets and non-sustained ventricular 
tachycardia 
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A study by O'Connor & Knoblauch84 aimed to investigate the population benefit and 
effectiveness of adding routine ECG to the AHA protocol.  The study was based on a complex 
scientific model which predicted that 16% of all athletes would be expected to have an 
abnormal ECG, whereas only 2% would have been abnormal with the current questionnaire 
and PE. However, with follow up only 1.3% of these athletes would have a cardiac problem 
which suggested ECG was an expensive tool to use in the cardiac assessment of athletes due 
to the number of potential false positive tests which are not cost effective and could place 
undue psychological stress on the athlete.  
 
The benefit of adding ECG to personal and family history and PE was examined by Baggish et 
al85.  This study screened 508 university athletes with personal and family history, PE, ECG 
and transthoracic echocardiogram (TTE). History and PE alone did not detect any of the 
abnormalities that were found on ECG and/or echocardiogram suggesting history and PE 
alone is not a useful screening tool.  However, the positive predictive value (PPV) of the ECG 
in identifying LVH was only 10.4% suggesting that ECG does not add significant useful 
information although it could be argued that it is useful in those with no abnormality 
(negative predictive value (NPV)=99.8%).  
 
A landmark study by Pelliccia et al62 on 1005 athletes suggested that new ECG 
recommendations reduced the number of athletes who were initially thought to have CV 
disease from 40% to 11% and increased specificity of the ECG to 95%.  This study suggests 
that the ECG can be a useful tool in cardiovascular screening if interpreted with caution.  
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1.11. Sex and Ethnic Differences in ECG and Echocardiogram  
Differences in the ECG and echocardiogram in Caucasian and black athletes have been widely 
reported86 87.  The prevalence of ECG abnormalities including repolarisation changes and T 
wave inversion are far more common in athletes of black origin however differences do exist 
amongst races.   
 
Basavarajaiah et al87 conducted a study in the UK comparing ECG and echo data in 300 
asymptomatic black male athletes (42% Afro-Caribbean, 40% West African, 18% East African) 
and 300 white male athletes. This also included control groups of 150 sedentary black males 
and 150 sedentary white males. They found T wave inversion was only prevalent in black 
athletes (12% v 0%).  Left ventricular wall thickness (LVPWd) was significantly greater in black 
athletes (11.3mm±1.6 v 10.0mm±1.5) with only 4% of white athletes demonstrating LVPWd 
greater than 13mm. Interestingly, there were no differences (p>0.05) in LVWT between black 
and white control groups (9.0mm±1.2 v 8.8mm±1.3).  With HCM being more common in 
black athletes, it raises the question of upper limits of normal on echo in this population.  
 
Gender differences can also be identified on ECG and echocardiogram.    Females have been 
shown to have a slower rate of repolarisation88 have a longer QT interval, and higher HR.  
Some other differences in the QRS complex are due to females having a smaller LV mass than 
males and smaller cavity size41 which is shown on echocardiogram.   
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1.12. Secondary Prevention  
Maron included information on survivors of cardiac arrest in one of his studies23. This is an 
important factor as without successful defibrillation, these would have been recorded as 
sudden cardiac deaths. It has been shown that early defibrillation in the event of cardiac 
arrest provides the greatest survival chances89. The UK survival rate for out-of-hospital 
cardiac arrest remains low at between 2 and 12%90. This is much lower than that reported in 
both Norway and the USA91. 
 
 A previous study by Schmied et al92 investigated the occurrence of cardiac events in football 
and assessed what preventative measures were taken by individual member nations of FIFA. 
This was a questionnaire based study which asked about the occurrence of any sudden 
cardiac arrest, SCD or sports-related death with further questions regarding resuscitation 
protocols and whether pre-participation screening was carried out. The response rate was 
74.1% (126 of 170 questionnaires) with 107 sudden cardiac arrests/SCD reported (as well as 5 
additional sports related deaths) from 52 of the 103 responding nations.  Only 20.5% 
survived (23 out of 112 SCD) with only 22 being treated with an AED on the pitch of whom 12 
survived (54.5%).   
 
 
 
 
 
 
 
 29 
 
1.13. Conclusions 
Sudden cardiac death remains an unknown quantity in terms of incidence and cause.  We 
need to establish mandatory reporting of sudden deaths due to cardiac causes worldwide 
both in the general population and an athletic population to analyse the true incidence of 
this problem.   
 
Many of the previous studies discussed here2 25 77 have introduced the concept of 
cardiovascular screening to reduce the incidence of SCD in young athletes given that they are 
thought to be more at risk than the general population. The results of such screening studies 
are mixed, with reductions in SCD shown in Italy but not in Israel.  Controversy also exists as 
to whether the Italian Model is truly the 'gold standard' programme. 
 
In 2008, the Scottish Government (in conjunction with the Scottish Football Association and 
University of Glasgow) established a cardiovascular screening programme in Scotland.  This 
programme was designed to establish whether the Italian Model was transferable to a 
Scottish population and to investigate the addition of echocardiography to the Model in 
terms of diagnosis of conditions.   
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1.14. Aims and Objectives  
This thesis will be presented in 2 parts with separate aims and objectives.  
The aim of Part One of this thesis was: 
 To investigate the incidence and causes of cardiac death in the young in Scotland  
 
This was the translated into the following objectives: 
 To use a national database provided by ISD to: 
- investigate what young people in Scotland die from 
- determine the incidence of cardiac death in the young in Scotland 
- Investigate the causes of cardiac death in the young in Scotland 
 To assess the proportion of these deaths for which the causes may be identified using 
cardiac screening  
 
 
The aim of Part Two of this thesis was: 
 To assess whether the addition of ECG and echocardiography adds benefit to current 
screening practice 
 
This was the translated into the following objectives: 
 To use the results of the Cardiac Assessment in Young Athletes (CAYA) programme to:  
- determine the incidence of left ventricular hypertrophy in a sporting population in 
Scotland 
- evaluate the sensitivity and specificity of ECG and echocardiography in identifying 
LVH in those undertaking athletic training 
- identify conditions such as LQTS, WPW and HCM in a young athletic population   
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Chapter 2 - Methodology  
This thesis is written in two parts.  Part one examines the epidemiology of sudden cardiac 
death in the young in Scotland and aims to provide information regarding the magnitude and 
causes of this problem.  Part two of the thesis analyses the results of the CAYA (Cardiac 
Assessment in Young Athletes) study to investigate the use of routine echocardiography in 
cardiovascular screening.   
 
2.1. Part One-Epidemiology  
Part one of the study aimed to examine the incidence of all deaths in the young with special 
consideration given to out of hospital (OOH) deaths, particularly those with a cardiac cause. 
Data was requested from and collated by the Information Services Division (ISD), a division of 
National Services Scotland, part of NHS Scotland. The ISD provides health information, health 
intelligence, and statistical services to support the NHS in Scotland.   
 
2.1.1. Data Source 
ISD were asked to provide information for the period 1986 to 2008 (inclusive) on deaths in 
individuals aged 0-35 years at time of death.  For each death they supplied the following 
data: 
- Unique identifier 
- Date of death (dd/mm/yyyy) 
- Age at death 
- Sex 
- Institution 
- Post Mortem 
- Postcode Sector 
- Health Board of Residence 
- Primary cause of death 
- All Secondary causes 
- Nature of injury marker 
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- Place of occurrence marker 
- Supplementary code for place of occurrence 
- Local government region 
- Health Board area 
- Year of death  
 
This information was generated by ISD from death certificate data which is collated by the 
General Register Office for Scotland (GRO). The death certificate includes information on the 
place of onset of the clinical event, the location of death as well as the cause of death.  For 
each death primary cause of death is provided, with additional secondary causes if recorded.   
ISD were also asked to look back to SMR (Scottish Morbidity Records) to see if the individuals 
had any specific diagnoses and to create a marker flag (0-no, 1-yes) for each: 
a) at any time since 1981 
b) within 1 year of their death 
c) within 5 years of their death 
 
Data regarding the health of patients in Scotland is collated as a catalogue of Scottish 
Morbidity Records (SMR’s).  These records identify the type of treatment received during an 
episode, recording all discharges following an acute hospital admission (SMR01) which was 
used in this research to record prior hospitalisation.  The SMR01 relates to all in-patient or 
day case discharges, associated with both elective and emergency admissions.  This record is 
generated following discharge from hospital to home, to another hospital or specialty or 
death.  SMR and death registration records, belonging to the same patient in Scotland, have 
been linked together in the Scottish Record Linkage System.  Each patient receives a primary 
diagnosis at discharge, which was used in this study.  
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For each of the above hospitalisations, ISD were asked to supply the following information: 
 
- Date of admission (dd/mm/yyyy) 
- Date of discharge 
- Hospital code  
- Age 
- Sex 
- Type of admission 
- Type of facility 
- Specialty 
- Length of stay 
- Year of admission 
 
This data was presented to us by ISD in an SPSS spreadsheet with 1001 variables on 41,049 
deaths. 
 
2.1.2. Coding of Data  
The cause of death was analysed from the International Clinical Diagnostic classification (ICD 
code) used in epidemiological research to classify diseases in clinical records such as medical 
notes and death certificates. ICD is the universally applied classification system for coding 
illness, medical diagnoses and external causes of injury.   
 
Causes of death in the current study were registered according to the International 
Classification of Diseases-9 (ICD-9), previous to year 1994, and the International Classification 
of Diseases-10 (ICD-10) from 1994 onwards.  ICD-9 has a total of 6969 codes, while there are 
12,420 ICD-10 codes, meaning deaths from 1994 onwards are coded into more distinct 
categories.  Doctors do not assign codes on the death certificate; instead the responsibility 
for the recording of codes for each death is undertaken by specialist clinical coders working 
within Medical Records departments. Errors in recording have been reported to be as high as 
20% for various reasons such as accuracy of diagnosis and human error as interpretation of 
information may vary93.   
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The General Register Office (GRO) for Scotland records and stores the cause of death for all 
patients based on information from the medical certificate issued at time of death.  Due to 
there being no information concerning the time from onset of symptoms to death available 
on the death certificate, I was unable to study 'sudden death'. This thesis will analyse deaths 
which occurred in-hospital and out-of-hospital.  
 
 
2.1.3. Location 
Information was available on the location of the initial clinical event.  These were chosen 
from one of the standard locations below: 
 Home 
 Farm 
 Mine/Quarry 
 Place of Industry 
 Sport/Recreation Area 
 Street/Highway 
 Public Building  
 Residential Institution 
 Other Specified Place 
 Unspecified Place 
 
 
Deaths were then categorised into those which occurred ‘in hospital’ and those which 
occurred ‘out-of-hospital’ (Table 2-1).  
 
Table 2-1: Locations of in and out-of-hospital death according to ISD information 
In-Hospital Out-of-Hospital  
NHS hospital Administration office 
Joint User hospital Health Centre/GP surgery 
Contractual hospital Clinic premises 
Non NHS Maternity  Non-institutional e.g.  home 
Private hospital School 
 Prison 
 Home for the elderly 
 Miscellaneous premises 
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2.1.4. Post Mortem Results  
For each death, information was provided on whether a post mortem (PM) had been carried 
out. No further information was available from the PM. In Scotland, the post mortem 
examination is generally requested by the Procurator Fiscal where a death is sudden and/or 
unexplained, or the cause of death is not obvious.  Deaths were classified into 6 categories as 
stated below: 
 
1. Post mortem was performed 
2. Post mortem was not proposed 
3. Post mortem may have been performed 
4. Post mortem was proposed and performed later 
5. Post mortem was proposed and not performed  
6. Post mortem was not proposed but was later performed 
 
These were than grouped as those which had undergone a PM examination (1, 4 and 6) and 
those which did not undergo a PM (2 and 5). For the remaining deaths, it is not clear whether 
a PM took place (3).   
 
 
2.1.5. Primary Cause of Death  
In this study, the primary cause of death from the death certificate was provided. Deaths 
were then categorised according to classifications from the World Health Organisation 
(WHO) coding system (Table 2-2).  Additional secondary causes were available but were not 
studied in this thesis.  
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Table 2-2: Causes of death according to WHO classifications with associated ICD-9 
and ICD-10 Codes  
Cause ICD-9 Codes ICD-10 Codes 
Infection 001-139 A00-B99 
Cancers 140-239 C00-D48 
Blood Diseases 280-289 D50-D89 
Endocrine/Metabolic Diseases 240-279 E00-E90 
Mental/Behavioral Disorders 290-319 F00-F99 
Diseases of Nervous System  320-389 G00=G99 
Circulatory Disease 390-459 I00-I99 
Respiratory Disease 460-519 J00-J99 
Diseases of GI System 520-579 K00-K93 
Diseases of Skin/Connective 
Tissue 
680-739 L00-M99 
Diseases of GU System 580-629 N00-N99 
Pregnancy/Childbirth 630-679 O00-O99 
Perinatal Conditions 760-779 P00-P96 
Congenital Malformations 740-759 Q00-Q99 
Symptoms/Ill Defined Causes 780-799 R00-R99 
Accidents E800-E929 V01-X59 
Drugs 304, 305, E850-E858 T36-T50 
Self Harm E950-E959, 960-979 X60-X84 
Assault E960-E69 X85-Y09 
Alcohol 980 Y15, F10, K70 
(GI=gastro-intestinal, GU=genito-urinary) 
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2.1.6. Cardiac Deaths 
Cardiac deaths were identified from ICD coding for circulatory causes of death (ICD-9 codes 
390-459, ICD-10 codes I00-I99) shown in Table 2-3.   
 
Table 2-3; Circulatory causes of death with associated ICD codes 
Chapter ICD 9 Codes ICD 10 Codes 
Acute Rheumatic Fever 390-392 I00-I02 
Chronic Rheumatic HD 393-398 I05-I09 
Hypertensive HD 401-405 I10-I15 
Ischaemic HD 410-414 I20-I25 
Pulmonary HD 415-417 I26-I28 
Other forms of HD 420-429 I30-I52 
Cerebrovascular disease 430-438 I60-I69 
Diseases of arteries, arterioles 
and capillaries 
440-449 I70-I79 
Diseases of veins, lymphatic 
vessels and lymph nodes 
451-459 I80-I89 
Other and unspecified disorders 
of circulatory system 
- I90-I99 
 
 
Cerebrovascular disease was excluded (ICD-9 codes 430-438, ICD-10 codes I60-I69). 
Congenital heart defects and Marfans syndrome were included (745-747, 759.82, Q20-Q28, 
Q87.4). ‘Sudden death, unknown’ was also included (ICD codes 798.1, 798.2 and R96). 
Sudden death unknown (798, R96) is later categorised within cardiac dysrhythmia due to the 
small numbers. Table 2-4 presents the causes of cardiac death as described by the ICD 
system with the associated ICD codes. 
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Table 2-4: Cardiac Causes of Death with ICD Codes  
Cause ICD-9 Codes ICD-10 Codes 
Congenital 745-747 Q20-Q28,Q87.4 
Coronary HD 410-414 I20-I25 
Cardiomyopathies 425 I42-I43 
Hypertensive HD 401-405 I10-I15 
Pulmonary HD 415-417 I26-I28 
Conduction Disorders 426 I44-I45 
Cardiac Dysrhythmias 427 I46-I49  
Heart Failure 428 I50 
Diseases of arteries 440-449 I70-I79 
Diseases of veins 451-459 I80-I89, I95 
Other 394-398, 420,423, 429 I05-I09, I30-I32, I34-I37, I51-
I52, I97-I98 
Endocarditis 421, 424 I33,I38-I39 
Myocarditis 422 I40-I41 
Sudden Death unknown 798 R96 
(HD=heart disease. Other includes includes valvular disease, pericarditis and 
diseases of pericardium and complications and ill-defined descriptions of HD) 
 
 
 
2.1.7. Previous Cardiovascular Diagnosis and Hospitalisation 
Previous diagnoses of cardiovascular disease were provided for analysis and were coded as in 
Table 2-5. Data on any previous hospitalisations was available in the spreadsheet from 
SMR01 records. 
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Table 2-5: Classification of previous cardiac diagnosis according to ICD coding  
Diagnosis ICD-9 Codes ICD-10 Codes 
Cardiovascular Disease 390-459 I00-99 
Coronary HD 410-414 I20-25 
Chest Pain 786.5 R07 
Angina 411, 413 I20, I24.9 
(HD=coronary heart disease) 
 
The date of admission and discharge were noted along with the clinical specialty.  Any history 
of cardiac surgery was also detailed.  Diagnosis, admissions and surgery were categorised 
into: 
a) All diagnoses since 1981 
b) Within 5 years of death 
c) Within 1 year of death 
 
Admissions for cardiac causes and previous diagnosis of cardiac disease were identified and 
cross tabulated with the primary cause of death to establish if a death was caused by a 
‘known cardiac condition’.   
 
 
2.1.8. Population and Calculation of Incidence of Death  
In order to calculate the incidence of death in this population, information on population size 
of Scotland for those aged 0-35 years was obtained using the mid-year population estimates 
from the General Register Office (GRO) for Scotland94.  These were calculated for each year 
(1986-2008) to allow calculations on the incidence of deaths. 
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Annual mortality incidence was calculated per 100,000 of the population by: 
 
(Number of deaths /estimated population size for each year) x 100,000 
 
The overall incidence of death in this population was calculated as: 
 
(Total no. deaths / sum of estimated populations over 23 years) x 100,000 
 
 
2.1.9. Analysis by Age 
Data was further analysed according to age and gender, in order to identify any trends or 
differences within groups.  Age categories were: 0 years (which were then excluded from 
analysis), 1-4 years, 5-9 years, 10-14 years, 15-19 years, 20-24 years, 25-29 years, 30-35 
years.  
 
2.1.10. Statistical Analysis 
All data was stored and analysed using SPSS 19.0, with graphs drawn using Microsoft Excel 
2010. Data is presented as absolute numbers, percentages and incidences per 100,000 
person years.  Results are presented with corresponding standard deviations (SD) and 
proportional 95% confidence intervals (CI).  
 
 
The incidence and causes (with corresponding 95% CI) of both in-hospital and out of-hospital 
deaths were reported by age and sex. Person-years were based on the number of persons in 
Scotland in the relevant age category from 1986 to 2008.  
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2.2. Part Two-Screening of Young Athletes 
Part 2 of the project aimed to evaluate the Scottish cardiovascular screening service, Cardiac 
Assessment in Young Athletes (CAYA).  The CAYA Study is a joint project between the Scottish 
Executive, the University of Glasgow and the Scottish Football Association. This is a voluntary 
service available to the public which is based at the Sports Medicine Centre at the National 
Stadium, Hampden Park. The programme also runs a number of Satellite sessions at other 
sites at a distance to make the testing available to a larger outlying population and to avoid 
postcode bias. The programme is based on the Italian Model, which is regarded as the Gold 
Standard screening protocol, but with the inclusion of an echocardiogram for all subjects.   
 
Each subject underwent the following tests as part of the screening protocol:  
 
 Personal and family history questionnaire 
 Physical examination 
 Resting 12-lead ECG  
 Echocardiogram 
I was responsible for administering all of the above with the exception of the 
echocardiogram which was carried out by a trained clinical physiologist. An experienced 
consultant cardiologist (Professor W. Stewart Hillis) was responsible for overseeing and 
reporting all results. A copy of all results were sent to the subject's GP and/or referring 
doctor with any necessary follow up arranged locally. Communication was also made with 
the patient following any positive results.  
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2.2.1. Subjects 
Cardiovascular screening in Scotland is a voluntary service available to the general public 
upon appointment free of charge. This service was initially set up to screen those aged 16-18, 
however younger ages were included due to demand and  The uptake of this service was 
poor amongst the general public with the majority of participants recruited from football 
clubs affiliated to the Scottish Leagues.  Footballers competing in European competition must 
be screened according to UEFA laws but no domestic laws exist below the Premier League. 
Subjects were recruited from 3 main sources:  
1. Volunteers from the general public who participate in organised sport (aged 12-19 
years) 
2.  Members of the Scottish Institute and regional Institutes for sport (aged 12-19 years; 
20-24 years; 25-29 years and 30-35 years) 
3. Footballers from Scottish Premier League and Scottish Football Leagues who required 
screening as part of mandatory licensing for team activities (aged 12-14 years; 15-19 
years; 20-24 years; 25-29 years and 30-35 years) 
 
Subjects completed a consent form which outlined potential implications regarding future 
employment, insurance and possible restriction from sporting competition. 
 
2.2.2. Personal and Family History Questionnaire 
Adapted versions of the personal and family history questionnaires detailed in the Lausanne 
Recommendations76 were completed by each participant. This included a symptomatic 
enquiry of the cardiovascular system and a family history of cardiovascular events as well as 
general health questions including any prescribed medications (see Appendix A).   
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2.2.3. Physical Examination 
Physical examination was carried out in accordance with the Lausanne Recommendations76, 
including examination of radial and femoral pulses and auscultation of the heart at all 4 
areas.  If a suspected murmur was heard, this was further investigated during the 
echocardiogram and a referral made if necessary.  
 
Height and weight were measured to the nearest 0.1cm/kg in bare feet and minimal clothing.  
Body surface area (BSA) was then calculated using the equation from Du Bois & Du Bois95.   
 
2.2.3.1. Blood Pressure Measurement 
The blood pressure was recorded on the right arm using an automated blood pressure cuff 
(Omron M7) once the subject was quietly in a supine position for 5 minutes. At least two 
measurements were taken for each subject, with the lowest value being recorded. Blood 
pressure was then categorised as in Table 2-6. Blood pressure machines were replaced every 
6 months to avoid any calibration issues. 
 
Table 2-6: Blood pressure classifications with associated systolic and diastolic 
measurements 
Classification Systolic Value Diastolic Value 
Normal <120mmHg <80mmHg 
Pre-Hypertension 120-139mmHg 80-89mmHg 
Stage I Hypertension 140-159mmHg 90-99mmHg 
Stage II Hypertension >160mmHg >100mmHg 
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2.2.3.2. Blood Pressure Sub-study 
Due to the high incidence of hypertension found, a small sub-study was undertaken following 
data collection to establish if the hypertension found in the CAYA study (stage I and II) was 
true hypertension or was due to ‘white coat’ syndrome. Subjects with stage I or stage II 
hypertension as per Table 2-6 were identified using the CAYA database from clubs with 
matched normal controls (BP below 120/80mmHg).  These 2 groups were then re-tested with 
domiciliary BP (DBP) to assess the prevalence of white coat hypertension in this population.  
 
Players were identified from the CAYA database and contacted via their Club Doctor before 
being provided with an additional information sheet and consent form (Appendix E).  
Standard Omron M7 digital blood pressure monitors were then issued to players and they 
were instructed on taking their blood pressure twice daily for 4 days according to NICE 
guidelines.   
 
2.2.4. Electrocardiogram 
A resting 12 lead electrocardiogram was recorded on all participants at 25mm/s and 
0.5mV/mm using a Mac 800 machine (GE Healthcare, UK). This provided automatic 
measurement of all standard intervals (QTc, PR and HR) (Figure 2-1) and gave qualitative 
reports. The assessment of LVH criteria were made by direct measurements using the 
Sokolow Lyon criteria (sum of S wave in V1 + R wave in V5 >35mm indicative of LVH)96 which 
was manually counted by an experienced cardiologist (WSH). The QT interval and corrected 
QT (QTc) were generated by the ECG machine according to Bazett's formula97. ECG changes 
were determined as significant abnormalities following The European Society of Cardiology’s 
(ESC) criteria (see Table 2-7).  
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Figure 2-1: Diagram of the QRS complex from ECG illustrating the measured PR 
and QT intervals (adapted from wikipedia)  
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Table 2-7: ECG Abnormalities determined as significant according to ESC criteria
98
  
P Wave 
-Left atrial enlargement: negative portion of the P wave in V1>0.1mV in depth and >0.4s in 
duration 
- Right atrial enlargement: peaked P wave in leads II and III or V1>0.25mV in amplitude 
- Prolonged PR interval >0.20s 
- Short PR interval <0.12s 
QRS Axis 
- Right axis deviation ≥ 120º  
- Left axis deviation -30 º to -90 º 
QRS Voltage (Sokolov Lyon Criteria for LVH) 
- S wave in V1+R wave in V5>35mm  
QRS Morphology 
- Partial RBBB (QRS>100ms) 
- RBBB (QRS>120ms) 
- LBBB (QRS>120ms) 
- Inter-ventricular conduction defect  
ST Segment and T Wave 
- Early repolarisation (ST elevation ≥2mm in>2 leads) 
- T wave flattening or inversion in >2 leads 
- Repolarisation pattern with particularly tall T waves (>15mm) 
Intervals 
- Prolonged QTc (using Bazett's formula) (>440ms in men; 460ms in women) 
Arrhythmia and Conduction Defects 
- Ectopic atrial rhythms 
- Atrial fibrillation or flutter 
- 1
st
 degree heart block 
- 2
nd
 degree heart block 
- Complete heart block 
(LVH=left ventricular hypertrophy, RBBB-right bundle branch block, LBBB-left 
bundle branch block, QTc=corrected QT interval) 
 
2.2.5. Echocardiogram 
Echocardiography was performed using standard 2D and M-mode trans-thoracic 
echocardiography (TTE) with Doppler measurements using an Acuson P50 or an Acuson CV70 
machine (Siemens, USA), and performed by 1 of 9 trained clinical physiologists. All 
physiologists were registered members of the British Society of Echocardiography and were 
working within the NHS. Results were overseen by Professor W S Hillis and reports sent to 
the GP and/or club doctor depending on the referral source.   
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Left ventricular dimensions were assessed by measuring inter-ventricular septal diameter 
(IVSd), posterior wall diameter (LVPWd) and left ventricular internal diameter (LVIDd) - all at 
end of diastole. These measurements were taken using M-mode from a 2D parasternal long 
axis view (see Figure 2-2).  
 
 
Figure 2-2: Diagram illustrating the measurements taken in M-mode during 
echocardiogram for intra-ventricular septal thickness (IVSd), left ventricular 
internal diameter dimension (LVIDd) and left ventricular posterior wall thickness 
(LVPWd) 
 
All valves (pulmonary, tricuspid, mitral and aortic) were assessed for structural and functional 
abnormalities using short axis views at their respective levels with colour Doppler to illustrate 
flow. An apical 4 chamber view with Doppler measurements was also used. All subjects were 
then assigned to one of three categories following TTE – those with no abnormal findings, 
those that could be considered abnormal but consistent with physiological remodeling and 
those that were abnormal and suggestive of underlying pathology according to left 
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ventricular dimension measurements (see Table 2-8).  All echocardiographic studies were 
performed to the Guidelines of British Society of Echocardiography and appropriate 
European Guidelines99.  
 
The right ventricle was visually assessed by the physiologist to ensure it was smaller than the 
left ventricle and eliminate any doubts over ARVC100.  Measurements were taken if 
appropriate. Clinical comments on ventricular function were made by the physiologists and 
cardiologist looking to exclude appearance of HCM. 
 
 
 
Table 2-8: Transthoracic echocardiography measurements used for diagnosis of 
left ventricular hypertrophy
85
  
Finding Males Females 
NORMAL ECHO 
Normal LV Wall Thickness IVSd or LVPWd <11mm IVSd or LVPWd <10mm 
 
MILDLY ABNORMAL: CONSISTENT WITH PHYSIOLOGICAL REMODELLING 
Mild LV Hypertrophy IVSd or LVPWd 11-13mm IVSd or LVPWd 10-12mm 
ABNORMAL:  SUGGESTIVE OF PATHOLOGY 
LV Hypertrophy IVSd or LVPWd >13mm IVSd or LVPWd >12mm 
(IVSd= intra-ventricular septal thickness, LVPWd=left ventricular posterior wall 
thickness) 
 
 
2.2.6. Ethical Approval 
Ethical approval was granted by University of Glasgow Medical Faculty Ethics Committee 
(Appendix B).  An information sheet (Appendix C) was provided to all interested participants 
detailing the procedures involved with all subjects then being asked to sign a written consent 
form (Appendix D) prior to inclusion in the study, which were countersigned by a parent or 
guardian if under 16 years.   
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2.2.7. Statistical Analysis 
All data was securely stored within a custom made CAYA database from which data was 
exported to SPSS 19.0.  Continuous data is presented as means (±SD).  Graphs were 
presented using SPSS and Microsoft Excel.   
 
Pearson correlations were undertaken for all continuous data with Spearman Rank 
correlations used for categorical data.  Paired t-tests were used to compare results in the 
blood pressure sub study.  The level of significance was accepted as p<0.05.  
 
Screening test statistics including sensitivity and specificity and negative and positive 
predictive values were calculated using 2x2 contingency tables based on the ability of each 
technique (ECG and echo) to identify athletes with left ventricular hypertrophy.  
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Chapter 3 - Results Part 1 
3.1.1. All Deaths aged 0-35 years in Scotland 1986-2008  
A total of 41,049 deaths were recorded in the young (ages 0-35 years) in Scotland between 
1986 and 2008.  The mean age of these deaths was 19.2 years (±12.5).  Of these deaths, 
27,748 (67.6%) were male, and 13,299 (32.4%) were female.  This gives a ratio of 2.1 male: 1 
female deceased.  The absolute number of deaths can be seen to decrease from 2045 deaths 
in 1986 to 1482 deaths in 2008 (27.5% decrease) (Figure 3-1).  Similar decreases are seen for 
both sexes although the number of deaths occurring in males always exceeds the number in 
females, and also shows more variation. 
  
Figure 3-1: Numbers of deaths per year in 0-35 year olds in Scotland 1986-2008 
 51 
 According to the mid-year population estimates (GRO Scotland), there was a 15.7% decrease 
in the size of the population of 0-35 year olds in Scotland between 1986 and 2008 (Figure 3-
2).  Similar declines were seen for both male (15.8% decrease) and female (15.7% decrease) 
sexes.   
 
Figure 3-2: Changes in mid-year population estimates for 0-35 year olds in 
Scotland 1986-2008 
 
 
Despite this decrease in the population size, Figure 3-3 shows a 14.0% decrease in incidence 
of mortality between 1986 (77.2 deaths per 100,000 population) and 2008 (66.4 deaths per 
100,000 population) and comparative declines in both sexes (male 13.6% v female 14.8%).   
The slight ‘peak’ that can be seen in 1988 can be accounted for by the Lockerbie Disaster 
(270 fatalities), with a smaller peak seen in 1996 being attributed to the Dunblane tragedy 
(18 deaths including 16 children).  
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Figure 3-3: All-cause mortality rates (per 100,000 of population) for men and 
women aged 0-35 years during 1986-2008 
 
 
3.1.2. Post Mortem Examination 
Table 3-1 shows the number of dead who did or did not undergo a post mortem 
examination.  Over half of all deaths (57.2%) had a post mortem carried out, with 11,641 
deaths not having a post mortem requested.  There are a number of deaths (2089 deaths, 
5.1%) where we cannot confirm if a PM took place or not.  
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Table 3-1: Performance of a post mortem in all dead aged 0-35 years 
Post Mortem No. of Deaths % of Deaths 
Was performed 23,500 57.2 
May have been performed 2089 5.1 
Not proposed 11,641 28.4 
Proposed & performed later 2876 7 
Proposed & not performed later 910 2.2 
Not proposed but performed later 33 0.1 
 
 
3.1.3. Place of Occurrence of Symptoms 
For the majority of deaths, the initial onset of symptoms were recorded to occur at home 
(37,426 deaths) (Table 3-2).  On initial examination a number of collapses which lead to 
death (n=180, 0.4%) were found to occur on the sports field.  This was of particular interest 
to part 2 of this study; however on closer examination we find that none of these were 
sports-related and were instead due to self-harm and assault.  
Table 3-2: Place of occurrence of onset of symptoms with absolute numbers and 
percentages 
Place of Occurrence No. of Deaths % of Deaths 
Home 37,426 91.2 
Farm 79 0.2 
Mine/Quarry 57 0.1 
Place of Industry 229 0.6 
Sport/Recreation Area 180 0.4 
Street/Highway 97 0.2 
Public Building 93 0.2 
Residential Institution 62 0.2 
Other Specified Place 1416 3.5 
Unspecified 1410 3.4 
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3.1.4. Location of Death 
The majority of deaths in 0-35 year olds (21,475 deaths, 52.3%) were found to have occurred 
in-hospital.  Of the 19,574 deaths that occurred out-of-hospital, 19,363 (47.2%) were 
recorded to occur in the home with deaths also occurring in nursing homes, prison and clinic 
premises (Table 3-3).   
 
Table 3-3: Location of deaths aged 0-35 years with absolute numbers and 
percentages 
Location of Death No. of Deaths % of Deaths 
Prison 143 0.3 
NHS Hospital 20,849 50.8 
Other Home (medical facility) 54 0.1 
Private Nursing Home/hospital 452 1.1 
Contractual Hospital 172 0.4 
Health Centre/GP Surgery 3 <0.1 
Home for the Elderly 9 <0.1 
Joint User Hospital  2 <0.1 
Non Institutional e.g. home 19,363 47.2 
Non NHS Maternity 1 <0.1 
Clinic Premises 1 <0.1 
 
Table 3-3 also identified 452 deaths occurred in private nursing homes and hospitals. This is 
an abnormally high number for a young population and warranted further investigation.  On 
examination, the majority of deaths (n=260) were in those aged 30-35 years.  The main cause 
of death within these private homes was cancer suggesting patients with terminal illness who 
were admitted for palliative treatment.   
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3.1.5. Deaths According to Age Category 
With the exception of a large number of deaths which occurred in infants (8514 deaths, 
21%), Figure 3-4 shows that the number of deaths increases with increasing age with the 
highest number of deaths occurring in the 30-35 year age category (10,887 deaths, 27%). 
 
 
 
 
Figure 3-4: All 41,049 deaths in the young (0-35 years) according to age category 
 
Figure 3-5 shows the numbers of deaths over time according to each age category. The 
largest change in deaths is those in infants (0 years).  This has significantly decreased from 
569 deaths in 1986 to 240 deaths in 2008.  This led to these infant deaths being removed 
from the remaining analysis.  All other age categories show variation in numbers of deaths 
over time, with the largest fluctuation seen in deaths in 30-35 year olds.  
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Figure 3-5: Line graph showing the absolute number of deaths according to age 
category over time 
 
 
3.1.6. Primary Cause of Death in 0-35 year olds 
Figure 3-6 illustrates the primary causes of death in the young between 1986 and 2008 
according to ICD classifications.  The largest causes of deaths are by accidents (8908 deaths, 
21.7%) and self-harm (5281 deaths, 12.9%).  The majority of medical related deaths are 
perinatal causes (4042 deaths, 9.8%), cancers (3894 deaths, 9.5%) and congenital defects 
(3153 deaths, 7.7%).  Table 3-4 shows the total number of deaths for each cause alongside 
the percentage of deaths for each category with associated 95% confidence interval.   
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Figure 3-6: Primary Causes of Death in the Young from 1986-2008 
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Table 3-4: Prevalence of Primary Causes of Death in the Young 1986-2008 
classified according to ICD-9 and ICD-10 coding with proportional 95% CI 
Cause of Death Total No. of Deaths Percentage (with 95% CI) 
Circulatory 2281 5.6% (5.3-5.8) 
Respiratory 1313 3.2% (3.0-3.4) 
Nervous System 1885 4.6% (4.4-4.8) 
GI System 542 1.3% (1.2-1.4) 
Endocrine 979 2.4% (2.2-2.5) 
Infection 777 1.9% (1.8-2.0) 
Cancer 3894 9.5% (9.2-9.8) 
Blood Disease 427 1.0% (0.9-1.1) 
Skin/Connective Tissue 108 0.3% (0.2-0.3) 
Mental/Behavioural Disorders 63 0.2% (0.1-0.2) 
GU System 153 0.4% (0.3-0.4) 
Pregnancy/Childbirth 108 0.3% (0.2-0.3) 
Congenital Defects 3153 7.7% (7.4-7.9) 
Perinatal 4042 9.8% (9.6-10.1) 
Accidents 8908 21.7% (21.3-22.1) 
Symptoms/Ill Defined Causes 1951 4.8% (4.6-5.0) 
Drugs 3071 7.5% (7.2-7.7) 
Alcohol 742 1.8% (1.7-1.9) 
Self-Harm 5281 12.9% (12.6-13.2) 
Assault 1371 3.3% (3.2-3.5 
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3.2. Infant Deaths 
Twenty one percent (8514 deaths) of all deaths in the young from 1986-2008 were in infants 
(0-1 years).  Of these deaths, the majority of these were due to perinatal causes (47 %) and 
congenital malformations (25%) (Figure 3-7).   
 
Figure 3-7: Primary causes of death in infants (0 years) between 1986 and 2008 
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3.3. All Deaths aged 1-35 years in Scotland 1986-2008 
Of the 41,049 deaths, 8514 (20.7%) were infant deaths (0 years), which were excluded from 
further analysis. The remainder of this thesis includes 32,535 deaths which occurred in those 
aged 1-35 years.  The mean age of these deaths was 24.2 years (±8.7).  Of the deceased, 
22,823 were males, and 9712 were females.  This gives a ratio of 3.2 male: 1 female 
deceased.   
 
 
The overall incidence of deaths in this population is 12 per 100,000 people. The number of 
deaths in 1-35 year olds is seen to be variable over time although a decrease can be seen 
from 1476 deaths in 1986 to 1242 deaths in 2008 (15.9% decrease), with a peak of 1664 
deaths in 1988 attributable to the Lockerbie Disaster (Figure 3-8).  A similar pattern can be 
seen for male deaths (decrease of 17.1% from 1053 deaths in 1986 to 873 deaths in 2008) 
whereas the total decrease is less for deaths in females (decrease of 12.8% from 423 deaths 
in 1986 to 369 deaths in 2008).  
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Figure 3-8: Number of deaths per year in 1-35 year olds in Scotland 1986-2008 
 
Despite the decrease in population size, results suggest there has been little change in the 
overall annual incidence of death in this age category when expressed per 100,000 of the 
population, with a visible peak in 1988 due to the Lockerbie Disaster (Figure 3-9).   
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Figure 3-9: Incidence per 100,000 population for those aged 1-35 years in Scotland 
1986-2008 
 
Variation in the incidence of death can be seen over time within age categories, but the  
highest incidence remains  in the 30-35 year category (mean 107.3 deaths per 100 000), 
followed by 25-29 year category (mean 86.3 deaths per 100,000).  The lowest incidence is 
seen in aged 5-9 years (14.8 deaths per 100,000), followed by 10-14 years (18.7 deaths per 
100,000) and 1-4years (29.8 deaths per 100,000) (Figure 3-10).   
 63 
 
Figure 3-10: The incidence of death per 100 000 population according to age 
category 
 
 
3.3.1. Location of Death in 1-35 year olds 
By removing the infant deaths, it can be seen that majority of deaths in the young (1-35 year 
olds) were found to occur out-of-hospital, with 17,998 occurring in the home (55.3%) and 
143 deaths (0.4%) in prison.  Of the remaining deaths, 13,898 occurred in-hospital with 494 
deaths occurring in nursing/residential homes (1.5%) and 2 deaths in clinic premises/GP 
surgery (<0.1%).   
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3.3.2. Primary Cause of Death in 1-35 year olds  
Figure 3-11 illustrates the primary causes of death in those aged 1-35 years.  Nearly a third of 
deaths are due to accidents (8778 deaths, 27%), with the other highest causes being self-
harm (5281 deaths, 16.2%), cancer (11.8%) and drugs (2459 deaths, 9.4%). 
 
Figure 3-11: Primary causes of death in ages 1-35years 
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3.4. Changing Causes of Death in 1-35 year olds 
On closer examination of the primary causes of death in this age group, we can see some 
variation over time (Table 3-5). The incidence of many causes of death (cancer, accidents, 
congenital) can be seen to decrease over time possibly due to improved healthcare providing 
better outcomes.  The incidence of deaths due to circulatory disease has also decreased from 
5.0 per 100,000 in 1986 to 3.3 per 100,000 in 2008.  
 
Table 3-5: The changing incidence of death for primary causes (according to ICD 
coding) per 100,000 of the population throughout the study period 
Cause 1986 1996 2008 
Circulatory 5.0 4.5 3.3 
Respiratory 3.1 2.4 1.7 
Nervous System 3.5 3.3 3.9 
GI 0.9 1.6 1.1 
Endocrine 2.8 1.3 1.5 
Infection 1.0 3.0 1.0 
Cancer 7.5 7.6 4.9 
Blood  0.5 0.2 0.2 
Skin/Connective 
Tissue 
0.3 0.2 0.1 
Mental/Behaviour 
Disorders 
0.2 >0.1 0.2 
GU 0.5 0.3 0.3 
Pregnancy/Childbirth 0.3 0.2 0 
Congenital 6.8 5.6 4.3 
Accidents 20.4 15.6 12.6 
Symptoms/Ill-Defined 
Causes 
6.0 2.6 7.6 
Drugs 0.6 6.7 7.6 
Alcohol 0.6 0.8 1.9 
Self-Harm 7.0 10.7 7.8 
Assault 1.4 3.3 1.2 
 
One of the largest decreases in incidence of death is from cancer.  Recent research compiled 
by Cancer Research UK has shown that since 1990, deaths from the 4 most common cancers 
(breast, bowel, lung and prostate) have fallen by almost a third in the UK.   
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3.5. Social Causes of Death in 1-35 years 
Analysis of the causes of death in 1-35 year age group highlighted a large number of deaths 
due to drugs and alcohol in Scotland (Table 3-5).  Figure 3-12 illustrates the increasing trend 
from 1986-2008 in the incidence of deaths due to drugs (0.6-7.6 per 100,000 with peak of 
11.8 per 100,000 in 2002) and alcohol (0.6-1.9 per 100,000 with peak 2.7 per 100,000 in 
2004) from 1986-2008, whereas the incidence of deaths due to cardiac cause has remained 
steady (3. 9 per 100,000 in 1986 and 3.8 per 100,000 in 2008).   
 
Figure 3-12: Incidence of death per 100,000 population over time for social causes 
(alcohol and drugs) and cardiac causes of death  
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3.6. All In and Out-of-Hospital (OOH) Deaths in 1-35 years 
Of the total 32,535 deaths recorded in those aged 1-35 years from 1986-2008, 18,204 deaths 
(56.0%) occurred out-of-hospital (OOH), and 14,331 deaths (44.0%) occurred in-hospital.  
Table 3-6 shows the mean age of out-of-hospital deaths is 25.0 years which is higher than in-
hospital deaths (23.1 years).  The number of male deaths is higher for both in and out-of-
hospital deaths.  
Table 3-6: Demographics of all deaths aged 1- 35 year old in Scotland 1986-2008 
 All Deaths In Hospital Out of Hospital 
Total Number 32,535 14,331 (44.0%) 18,204 (56.0%) 
Mean Age 24.2 23.1 25.0 
Males 22,823 8992 (39.4%) 13,831 (60.6%) 
Females 9712 5339 (55.0%) 4373 (45.0%) 
 
 
3.6.1. Post Mortem Examination  
In total, 22,421 post mortems were carried out (71.0%) in 1-35 year olds who died from 
1986-2008.  Deaths which occurred out-of hospital had a higher rate of post mortem (83.6% 
deaths) examinations than those that occurred in-hospital (54.7% deaths) (Table 3-7). 
 
Table 3-7: Numbers of In and Out-of-Hospital Post Mortems 
 Post Mortem No Post Mortem Totals 
In Hospital 7518 (54.7%) 6225 (45.3%) 13,743 
Out of Hospital 14,903 (83.6%) 2913 (16.4%) 17,816 
Totals 22,421 (71.0%) 9138 (29.0%) 31,559 
 
An additional 976 deaths may have had a post mortem, but further information was not 
available from our source (588 in-hospitals and 388 out-of-hospitals). 
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3.6.2. In and Out-of Hospital Death according to Age Category  
Deaths in younger age groups (1-4, 5-9 and 10-14 years) were found to occur more 
frequently in-hospital. With increasing age (15years+), the number of out-of-hospital deaths 
exceeds the number of in-hospital deaths in the young (Figure 3-13).  This is greater in 25-29 
age group (2725 deaths v 4360 OOH deaths), and is greater still in 30-35 year category (4762 
deaths v 6125 OOH deaths).   
 
 
Figure 3-13: Number of in-hospital and out-of-hospital deaths according to age category 
 
3.6.3. Primary Causes of In and Out-of-Hospital Death in 1-35 year olds 
In total, 18,204 deaths occurred outside-of-hospital (OOH) (56.0%), with 14,331 deaths 
occurring inside hospital. Most medical causes of death were found to occur more frequently 
in-hospital, whereas deaths due to accidents, self-harm and drugs occurred more frequently 
out-of-hospital (Table 3-8).   
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Table 3-8: Primary causes of in and out-of-hospital death aged 1-35 years 
according to ICD coding 
Cause of Death Total Number of 
Deaths 
In-Hospital Deaths Out-of-Hospital 
Deaths 
Circulatory 2200 1393 (63.3%) 807 (36.7%) 
Respiratory 1170 747 (63.8%) 423 (36.2%) 
Nervous System 1710 933 (54.6%) 777 (45.4%) 
GI System 503 351 (69.8%) 152 (29.2%) 
Endocrine 903 491 (54.4%) 412 (45.6%) 
Infection 657 543 (82.6%) 114 (17.4%) 
Cancer 3829 2510 (65.6%) 1319 (34.4%) 
Blood Disease 403 321 (79.7%) 82 (19.3%) 
Skin/Connective Tissue 105 91 (86.7%) 14 (13.3%) 
Mental/Behavioural 
Disorders 
61 43 (70.5%) 18 (29.5%) 
GU System 146 119 (81.5%) 27 (18.5%) 
Pregnancy/Childbirth 108 91 (84.3%) 17 (15.7%) 
Congenital Defects 1005 781 (77.7%) 224 (22.3%) 
Perinatal 21 19 (90.5%) 2 (9.5%) 
Accidents 8722 3288 (37.5%) 5434 (62.5%) 
Symptoms/Ill Defined 
Causes 
515 131 (25.4%) 384 (74.6%) 
Drugs 3127 668 (21.8%) 2459 (78.2%) 
Alcohol 742 391 (52.7%) 351 (47.3%) 
Self- Harm 5281 789 (14.9%) 4492 (85.1%) 
Assault 1327 631 (47.6%) 696 (52.4%) 
Total Number 32,535 14,331 18,204 
 
 
3.7. All Cardiac Deaths aged 1-35 years 
From circulatory ICD codes, cerebrovascular causes were excluded and congenital cardiac 
defects were included to create ‘cardiac’ causes of death.  A total of 2084 cardiac deaths 
occurred in those aged between 1 and 35 years old from 1986-2008.  Of these, 1405 were 
male and 679 were female, giving a ratio of 2.1 male: 1 female deceased.  In total, 1317 
deaths occurred in-hospitals (63.2%), and 767 deaths occurred out-of-hospital.  
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Figure 3-14: Incidence of cardiac death, in-hospital and out-of-hospital per 
100,000 population 
 
Figure 3-14 illustrates that the overall incidence of cardiac death has both increased and 
decreased between 1986 and 2008, with the 2008 figure being lower (4.0 per 100,000 in 
1986-2.9 per 100,000 in 2008).  This is also true for in-hospital deaths which have decreased 
over the 23 year study period (2.6 per 100,000 to 1.6 per 100,000).  However, the number of 
OOH cardiac deaths remains steadier over time with a smaller reduction (1.5 per 100,000 to 
1.3 per 100,000).   
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3.7.1. All Cardiac Deaths aged 1-35 years according to Age Category  
The number of deaths attributed to a cardiac cause, were found to increase with increasing 
age.  Figure 3-15 shows the incidence to be highest in those aged 30-35years (909 deaths, 
44%), following by those aged 25-29years (373 deaths, 18%). 
 
 
 
Figure 3-15: All 2087 cardiac deaths aged 1-35 years according to age category 
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3.7.2. Primary Cause of Cardiac Death in 1-35 year olds  
Of the 2084 cardiac deaths, 30% (624 deaths) were due to coronary heart disease. 24.8% 
were due to congenital heart defects (516 deaths) and 9.8% were due to cardiomyopathies 
(205 deaths) (Figure 3-16). 
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Figure 3-16: Primary causes of cardiac death in 1-35 year olds in Scotland 1986-
2008 
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3.7.3. Post Mortem Examination for Cardiac Deaths 
Not all cardiac deaths were confirmed by post mortem examination, with some information 
on whether a PM was carried out not available (527 deaths, 25.3%).  In total, 69.1% of 
cardiac deaths had a PM carried out (1441 deaths) to confirm a cardiac cause of death (Table 
3-9). 
 
Table 3-9: Numbers of post mortems carried out to confirm cardiac death 
Cause of Death No. of Deaths No. of PM Percentage of Deaths 
with PM 
Congenital 516 236 45.7% 
Coronary HD 624 531 85.1% 
Cardiomyopathy 205 130 63.4% 
Hypertensive HD 38 22 57.9% 
Pulmonary HD 95 54 56.8% 
Conduction Disorders 12 7 58.3% 
Cardiac Dysrhythmia 83 52 62.7% 
Heart Failure 29 21 72.4% 
Diseases of Arteries 53 35 66.0% 
Diseases of Veins 109 90 82.6% 
Other 216 182 84.7% 
Endocarditis 37 20 54.1% 
Myocarditis 68 61 89.7% 
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3.7.4. In and Out-of-Hospital Cardiac Deaths by Age Category  
The number of in-hospital deaths is found to be high in the 1-4 year age category and then 
decreases before it increases steadily from aged 5-35 years.  OOH deaths increase steadily 
with age with the largest increase being seen 30-35 year age category (Figure 3-17).   
 
 
Figure 3-17: Numbers of in-hospital and out-of-hospital cardiac deaths 
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3.7.5. Causes of In and Out-of-Hospital Cardiac Death  
Table 3-10 provides information of the total number of deaths per cause as well as 
information regarding the numbers of in and out-of-hospital cardiac deaths by cause. The 
majority of deaths are attributable to coronary heart disease (629 deaths, 30.0 %) and 
congenital malformations (516 deaths, 24.8 %).   
 
Table 3-10: Numbers of in and out-of-hospital cardiac deaths 1-35 years with 
according ICD codes  
Cause of Death ICD-9 
Codes 
ICD-10 
Codes 
All Deaths No. In 
Hospital 
Deaths 
No. Out-of-
Hospital 
Deaths 
Congenital 745-747 
759.82 
Q20-28, 
Q87.4 
516 (24.8%) 439 (85.1%) 77 (14.9%) 
Coronary HD 410-414 I20-25 624 (30.0%) 279 (44.7%) 345 (55.3%) 
Cardiomyopathy 425 I42-43 205 (9.8%) 122 (59.5%) 83 (40.5%) 
Hypertensive HD 401-405 I10-15 38 (1.8%) 20 (52.6%) 18 (47.4%) 
Pulmonary HD 415-417 I26-28 95 (4.6%) 80 (84.2%) 15 (15.8%) 
Conduction 
Disorders 
426 I44-45 12 (0.6%) 8 (66.7%) 4 (33.3%) 
Cardiac 
Dysrhythmia 
427 I46-49 83 (4.0%) 58 (69.9%) 25 (30.1%) 
Heart Failure 428 I50 29 (1.4%) 14 (48.3%) 15 (51.7%) 
Disease of arteries 440-449 I70-79 53 (2.5%) 48 (92.3%) 5 (7.7%) 
Disease of veins 451-459 I80-89, I95 109 (5.2%) 75 (68.8%) 34 (31.2%) 
Other 394-398, 
420, 423, 
429 
I05-09, I30-
32, I34-37, 
I51-52, I97-
98 
 
215 (10.3%) 
 
91 (42.6%) 
 
124 (57.4%) 
Endocarditis 421, 424 I33, I38-39 37 (1.8%) 32 (86.5%) 5 (13.5%) 
Myocarditis 422 I40-41 68 (3.3%) 51 (75.0%) 17 (25.0%) 
(CHD: coronary heart disease, HD: heart disease) 
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Figure 3-18: Histogram showing proportional %'s of in and out-of-hospital deaths 
for each cardiac cause of death 
 
With the exception of CHD and heart failure, the majority of each cause of cardiac death 
occur in hospital (see table 3-10 and figure 3-18)   The split for CHD is 44.7% in-hospital (279 
deaths) and 55.3% (345 deaths) with heart failure deaths being more evenly split at 48.3% in-
hospital and 51.7% out-of-hospital.   
 
Figure 3-19 illustrates that the main 3 primary causes of cardiac death are the same for both 
in-hospital and out-of-hospital deaths but that the incidence is different.  The main cause of 
in-hospital cardiac death is from congenital malformations (439 deaths), followed by CHD 
(279 deaths) and cardiomyopathy (122 deaths).  The majority of out-of-hospital deaths are 
due to CHD (345 deaths), followed by cardiomyopathy (83 deaths) and congenital 
malformations (77 deaths).   
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a) Primary Cause of In-Hospital Cardiac Deaths aged 1-35years  
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b) Primary Cause of Out-of-Hospital Cardiac Deaths aged 1-35years  
Figure 3-19: Primary causes of in-hospital and out-of-hospital cardiac death in 
those aged 1-35 years (CHD=coronary heart disease, HD=heart disease)  
 
 
 78 
The causes of cardiac death vary amongst age categories (Figure 3-20), with congenital 
deaths being most common in the 1-4 year age group (171 deaths, 79.2%) and then 
decreasing steadily to smaller numbers (62 deaths, 6.8%) in the 30-35 year age category. 
Deaths due to CHD are more apparent in older age categories, particularly 30-35 year group 
(458 deaths, 50.4%) and the 25-29 years group (125 deaths, 33.5%).  The number of deaths 
due to cardiomyopathies appear to vary most across the age categories with the highest 
number in those aged 15-19 years (35 death; 18.8%) and similar percentages of deaths in 
those aged 10-14 (9 deaths, 10.7%) years and 20-24 years (30 deaths, 11.7%). 
 
 
Figure 3-20: Proportional % causes of OOH cardiac deaths by age category 
(CHD=coronary heart disease, HD=heart disease) 
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3.8. Out-of-Hospital Cardiac Death  
Of the 2084 deaths attributable to a cardiac cause, 767 (36.8%) occurred out-of-hospital and 
so could be considered to be 'sudden' in nature.  Results show that the main causes of out-
of-hospital death are similar to those which occurred in-hospital, but differences do exist in 
the ages of these deaths. 
 
3.9. Confirmed Cardiac Death 
For a death to be confirmed as due to a cardiac cause, a post mortem examination must have 
taken place. Of the 2083 cardiac deaths analysed, 1442 had undergone a PM (69.2%)  Of the 
767 out-of-hospital cardiac deaths, 629 had undergone post mortem (82%), with 813 of 1316 
(61.8%) of in-hospital deaths having undergone PM.  
 
Table 14 and Figure 3-21 show that with the exception of conduction disorders and diseases 
of the arteries, there are a higher percentage of PM's carried out for deaths which occur out 
of hospital (OOH).  All deaths that occurred OOH caused by endocarditis had a PM, compared 
to less than half (47.9%) that occurred in-hospital.  However, it also shows that there are a 
large number of deaths (both in and out-of-hospital) which received a cardiac diagnosis 
without post mortem. 
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Table 3-11: Numbers of deaths which underwent PM for a confirmed cardiac 
diagnosis  
Cardiac Cause of 
Death 
In-Hospital 
Cardiac Deaths 
No. In Hospital 
Deaths with PM 
OOH Cardiac 
Deaths 
No. Out-of-
Hospital Deaths 
With PM 
Congenital 439  197 (44.9%) 77  39 (50.6%) 
Cornonary HD 279  231 (82.8%) 345  300 (87.0%) 
Cardiomyopathy 122  70(57.4%) 83  60 (72.3%) 
Hypertensive HD 20  6 (30.0%) 18  16 (88.9%) 
Pulmonary HD 80  42 (52.5%) 15  12 (80.0%) 
Conduction 
Disorders 
8  5 (62.5%) 4  2 (50.0%) 
Cardiac 
Dysrhythmia 
58  34 (58.6%) 25  18 (72.0%) 
Heart Failure 14 8 (57.1%) 15  13 (86.7%) 
Disease of arteries 48 32 (66.7%) 5  3 (60.0%) 
Disease of veins 75 60 (80.0%) 34  30 (88.2%) 
Other 92 67 (73.6%) 124  115 (92.7%) 
Endocarditis 32 15 (47.9%) 5  5 (100.0%) 
Myocarditis 51 45 (88.2%) 17  16 (94.1%) 
(OOH=out-of-hospital, PM=post mortem) 
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a) In-hospital deaths 
 
b) Out-of-hospital deaths 
Figure 3-21: Histogram showing percentage proportions of a) in-hospital and b) 
out-of-hospital deaths which underwent post mortem examination (PM=post 
mortem) 
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3.10. OOH Cardiac Death with No Prior History of Cardiovascular Disease 
Out of hospital cardiac deaths which had been confirmed by PM were investigated to see 
whether there had been any previous cardiac diagnosis or history of hospital admission.  
Figure 3-22 shows the incidence of OOH cardiac death to be variable throughout the study 
period. 
 
 
Figure 3-22: Incidence of OOH cardiac death as confirmed by PM per 100,000 of 
the population 
 
Results showed 629 confirmed OOH cardiac deaths following PM examination (30.2% of all 
cardiac deaths). Of these 629 confirmed OOH cardiac deaths, 462 were male (73.4%) and 167 
were female.  Figure 3-23 shows that the number of these deaths increases with age, with 
59.1% of deaths (372 deaths) occurring in the 30-35 year category. 
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Figure 3-23: Number of confirmed OOH cardiac deaths according to age category 
 
 
The majority of OOH cardiac deaths confirmed by PM examination are due to coronary heart 
disease (300 deaths, 47.7%), followed by 'other' category which includes valvular disease, 
pericarditis and diseases of pericardium and complications and ill-defined descriptions of HD 
(115 deaths, 18.3%), and cardiomyopathy (60 deaths, 9.5%) (Figure 3-24). 
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Figure 3-24: Primary causes of confirmed OOH Cardiac Deaths 
 
 
 
Figure 3-25: Causes of confirmed cardiac death according to age category 
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3.11. OOH Deaths due to Coronary Heart Disease 
There were 300 deaths due to coronary heart disease that were confirmed by PM 
examination.  According to our data, only 13 of these 300 (4.3%) had a previous diagnosis of 
coronary heart disease, with 10 (76.9%) of these being diagnosed in the year leading up to 
death.   
 
3.12. OOH Deaths due to Congenital Heart Disease 
There were 39 deaths due to congenital heart disease that were confirmed by PM 
examination.  Results show that only 14 (35.9%) of these deaths had a prior diagnosis of 
congenital heart disease, with 11 (28.2%) being noted as having a diagnosis of cardiovascular 
disease.   
 
3.13. OOH Deaths due to Cardiomyopathy 
There were 60 deaths due to cardiomyopathy that were confirmed by PM examination.  Data 
shows that only 17 of these 60 (28.3%) had a previous diagnosis of cardiovascular disease, 
with 7 (41.2%) of these being diagnosed in the year leading up to death.  From the 
information available, it is not possible for us to differentiate between types of 
cardiomyopathy such as DCM or HCM. 
 
3.14. OOH Deaths due to Dysrhythmia  
It has been discussed that deaths due to arrhythmia cannot be diagnosed at PM without an 
ECG prior to death.  Therefore we can assume that those with a dysrhythmia as primary 
cause of death have either had a prior diagnosis or a negative PM. Only 2 deaths were 
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identified as having a dysrhythmia as cause of death and both of these deaths had a prior 
diagnosis of cardiovascular disease and atrial fibrillation.   
 
3.15. Potential Cardiac Deaths 
There are an additional number of deaths which could be attributed to cardiac causes (Class 
B cardiac deaths).  Table 3-12 identifies 1012 deaths which according to Cardiac Risk in the 
Young (CRY) 27could be attributed to cardiac causes. CRY suggest that in the cases outlined in 
Table 3-12, could be due to an underlying undiagnosed cardiac arrhythmia which would 
present a negative PM.   
 
Table 3-12: Details of the 1012 deaths (age 1-35 years) which according to CRY, 
could be attributable to cardiac causes 
ICD Codes Cause No. of Deaths 
345.9, G40.9 Epilepsy, unspecified 573 
345.3, G41.9 Status epilepticus 82 
493.1, J46 Status asthmaticus 53 
E910, W69, W65, W67, W69, 
W70 
Accidental drowning 266 
W73 Other specified drowning 2 
W74 Unspecified drowning 21 
E913.0, W75 Accidental suffocation in bed 15 
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Chapter 4 -Discussion Part 1 
This is the first study to investigate the incidence and all causes of death in a young 
population (1-35 years) in Scotland.  Previous studies have examined drugs deaths101, 
suicides102 and medical causes103 104 individually in this age group but this study will put these 
into a wider context. Deaths that occurred both in and out-of-hospital were then 
investigated, before focussing on those due to a cardiac cause, particularly those which 
occurred out-of-hospital and those which could have potentially been identified by cardiac 
screening.   
 
4.1. All Deaths in Scotland 1986-2008 
In total there were 41,049 deaths in those aged 0-35 years in Scotland between 1986 and 
2008.  During this 23 year period, there was a 14% reduction in overall mortality with similar 
results being seen in both sexes (Figure 3-1).  Previous evidence suggests Scotland has one of 
the worst mortality rates in Western Europe, and that the reductions seen in this study are 
lower in comparison to other countries105-107.  Most evidence in this area features those of 
working age (15-74 years) which makes direct comparisons with our younger cohort difficult 
18 107 108.  
 
A large number of deaths occurred in infants (21%, 8514 deaths) with perinatal deaths shown 
to significantly decrease over the study period.  This is a positive indication that pre and post 
natal care has improved over recent years with advances in neo-natal care and surgical 
techniques. The greatest number of deaths occurred in those aged 30-35 years (10,887 
deaths, 27%). The majority of deaths in this study occurred following a collapse in the home 
(91.2%) with 51.7% of these leading to death in the home. No information was available on 
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the circumstances surrounding the deaths in this study and the time from the subject being 
well, to collapse and death so it is impossible to ascertain which deaths can be deemed 
‘sudden’. This led to us focusing on OOH deaths in this study which had been used in 
previous studies17. 
 
4.1.1. Use of Post Mortem 
In Scotland, a post mortem (PM) will be carried out when the procurator fiscal feels it is 
required to establish the cause of death particularly if the death was sudden and/or 
unexpected. A PM may also be requested by the hospital in which case consent must be 
obtained by the next of kin.  Without a post mortem, cause of death can be wrong in up to 
30% of cases109, but even after a PM the exact cause of death may remain unknown.   Our 
results show that in 68.9% of deaths in 1-35 year olds, a PM took place.  We would expect 
this rate to be higher than that of the entire population as PM’s are more routinely 
undertaken in young, previously healthy subjects who die suddenly. The post mortem rate in 
England and Wales is reported to be almost double the rate in Scotland, possibly due to the 
fact that the option exists in Scotland for an external examination of a body before 
dissection110.  
 
Eighty two percent of OOH cardiac deaths underwent PM. Due to the nature of the study, 
results of the PM were not available and cause of death was taken from the death certificate. 
If the post mortem is negative, the pathologist should review the patient history and conduct 
pathological and histological testing.  Tissue should also be kept for genetic and DNA 
sampling under the Tissue Act; however this remains controversial.  We have no information 
regarding whether the recording of a specific cause of death was following the result of 
histology and in some cases such as HCM, diagnosis should not be made without this 
additional testing.   
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4.2. Incidence and Causes of Cardiac Death  
In the current study, 6.4% of deaths in those aged 1-35 years (n=2084) were due to cardiac 
causes giving an annual incidence of 0.33 deaths per 100,000 population. Although Scotland 
is a smaller country, this figure is much lower incidence than is quoted by Cardiac Risk in the 
Young (CRY) who have suggested that there are 12 SCD every day in the UK.  Papadakis et al27 
found the incidence of SCD in England and Wales to be 1.8 deaths (±0.08) per 100,000 per 
year (3409 deaths) over a 4 year period (2002-2005) in those aged 1-34 years in a study 
based on governmental data. In the Netherlands, an incidence of 1.62 deaths per 100,000 
person years was found but SCD was based on an ICD code for acute MI only and included 
deaths up to the age of 40 years17.  
 
 As in previous studies17 23 111, a higher incidence of OOH death was found in males, with a 
ratio of 2.1male: 1 female death.  It is accepted that the incidence of SCD increases with age 
due to a rise in the prevalence of coronary artery disease61 111-113. Almost a third of our 
cardiac deaths were due to CHD (n=624; 29.9%), with 24.8% due to congenital heart disease 
(n=516) and 9.8% due to cardiomyopathies (n=205).  These proportions are the same as in 
the rest of the UK where a study by Papadakis et al27 found approximately one third of 
deaths were  due to ischaemic HD (33.5%), with 56% of these due to acute MI. 
Cardiomyopathies were the second commonest cause (27% of all deaths) of definite cardiac 
deaths (12% of all deaths DCM and 5% HCM) with SADS accounting for 14% of deaths27.  A 
study in Ireland which only included cases with a confirmed cardiac cause of death following 
PM, found the leading cause of death in 15-35 year olds to be SADS (26.7%) followed by CAD 
(20.7%) and HCM (14.7%)114.  The remaining deaths were due to idiopathic LVH (10.3%), 
myocarditis (6.0%), congenital HD (8.6%), DCM (2.7%), ARVC (1.7%) and a number of 
conditions with only 1 death114. 
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In Italy the largest cause of SCD in the young has been shown to be ARVC2, a condition which 
is relatively rare elsewhere in the world suggesting a geographical link to this condition. In 
America it is HCM23 is the largest cause of SCD but they have a large black population who 
are more susceptible to this condition due to genetics, Our different results suggest that the 
main causes of SCD in the young are changeable depending on geographical location and 
ethnic factors. Our population were mainly white, whereas HCM is more common in blacks 
and ARVC is not a common cause of death outside Italy.  Cardiovascular screening in these 
countries is designed to target those at risk from SCD from structural conditions such as HCM 
and ARVC.  Our results show that these conditions are not as prevalent in Scotland and that 
perhaps our causes of death do not support the introduction of such screening models.    
 
 
4.3. Prior Diagnosis of Cardiovascular Disease 
Some causes of cardiac death such as conduction disorders or cardiac dysrhythmias cannot 
be identified using PM unless an abnormal ECG has been performed prior to death. In this 
study, only 4 deaths were due to cardiac dysrhythmia with 2 (both of which occurred OOH) 
undergoing PM with a prior diagnosis of AF. Of 83 deaths due to conduction disorders, only 
30.1% occurred OOH none of them having a previous cardiovascular diagnosis. Seventeen 
OOH cardiomyopathy deaths (20.5%) with post mortem had a previous diagnosis of 
cardiovascular disease.   
 
4.4. Cardiac Deaths identifiable by Screening 
The introduction of cardiac screening is designed to reduce the number of SCD's from 
conditions which can be identified by cardiac investigations.  In Italy the rate of SCD has been 
reduced from 3.6 deaths per 100,000 person years to 0.43 deaths per 100,000 person years 
after the introduction of a mandatory screening service2 although these results have not 
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been replicated in any other countries.  In this study, there are very few deaths (0.9% of 
total) which could potentially have been identified through screening (205 cardiomyopathies, 
12 conduction disorders and 83 cardiac dysrhythmias).  
 
The commonest cause of cardiac death in this study was CHD (29.9%).  Although family 
history can be an important factor in the development of CHD, this condition would not be 
identified by ECG or echocardiogram in asymptomatic patients.  This would require 
additional tests such as exercise testing or angiography which would not be cost effective or 
practical.  The low number of arrhythmic deaths in this study may be an under-
representation of the truth as any evidence of CAD could lead to a mis-diagnosis at PM.  
 
The aim of screening is to identify those with a previously undiagnosed condition. This study 
found that the majority of cardiomyopathy deaths occur in those age 15-19 years with 
Papadakis et al27 finding a greater proportion of these deaths in those aged 10-19 years. This 
suggests that cardiac screening should be carried out at around 14 years old for maximal 
disease identification.   
 
4.5. Reliability of the Data 
The lack of a national register to record sudden deaths means that using data from ISD is the 
most accurate way to analyse such deaths. It is acknowledged that the biggest limitation to 
this epidemiological study is that we were unable to examine the death certificates or post 
mortem reports ourselves and are reliant on the information provided by ISD. 
Misclassification of deaths is possible but given the high incidence of PM in this study 
(approximately 70%) we assume this would reduce this problem. Given the ambiguity 
surrounding many sudden cardiac deaths, some arrhythmic deaths may have been mis-
coded.  
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The robustness of the ICD coding system determines the reliability of the data.  Codes are 
assigned by clinical coders employed within medical records departments within hospitals.  
This information is processed from information in hospital case notes and death certificates.  
There is no mechanism for us to confirm the reliability of the data.  We know for certain who 
died (unique identifier only), at what age and on what date but we do not know how 
accurate the rest of the information is.  For example, we know that during the research 
period (1986-2008) there was one high profile death where the initial collapse happened 
during a football match (Phil O’Donnell playing for Motherwell on 29th December 2007), yet 
when we investigate this further this collapse is coded as happening at home. 
 
Some of the ICD codes are also unclear. There is no distinct code for ARVC and instead it is 
coded under ‘other cardiomyopathies’.   The term 'sudden adult death syndrome' or SADS is 
now commonly used for deaths where there are no signs or illness or injury at PM and the 
heart remains morphologically normal (negative PM).  However, until 2012 there was no 
guidance for pathologists how these deaths should be coded (now these are coded as I49.9 
cardiac arrhythmia, unspecified), meaning that these deaths could be assigned to a variety of 
different codes making analysis of true numbers difficult. 
 
In Ireland, a SCD in the Young Registry was established in 2007 by the Health Services 
Executive to identify all sudden deaths in those aged 15-35 years (1-14 years are held on a 
paediatric mortality register).  A similar Register exists in Italy whereas other studies23 25 have 
relied on newspaper and media reports to calculate numbers of deaths. 
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4.6. Limitations 
The initial study set out to examine causes of sudden cardiac death and smoking was not 
thought to be an important factor.  Given the high prevalence of CHD found, it would be 
reasonable to have examined this and other lifestyle factors or to introduce this in future 
screenings. The study was limited by the retrospective nature and the reliance on correct 
information being placed on death certificates by clinical coders, and this information being 
reliably transferred to the ISD database.  A more accurate study would have examined death 
certificates itself, or collected data prospectively from procurator fiscal offices.   
The choices of which ICD codes to include for cardiac deaths could be questioned and may be 
different between studies.  Errors can occur in communication between the attending doctor 
and the clinical coder in the cause of death recorded as this is open to individual 
interpretation with the coders’ experience often a major influence93. Some causes of death 
could be deemed different by 2 pathologists depending on the circumstances of the death 
and information available. To improve reliability of the data, it would have been useful to 
access the death certificates myself, to reduce any error and validate the database but this 
was not possible.  
 
   
4.7. Summary 
The majority of deaths in young people in Scotland were found to be due to accidents, 
cancer, self-harm and drugs identifying a social problem in Scotland.  Cardiac deaths 
compose a small number of deaths in this age group (6.4%) with most occurring in-hospital 
(63.2%). Due to the nature of the data, the most workable definition of unexplained death in 
this study was 'out-of-hospital' death. These OOH deaths, where the deceased has not 
previously been diagnosed with cardiovascular disease are the ones which would be targeted 
by a screening programme. 
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The majority of OOH cardiac deaths occurred in those aged 30-35 years and were due to 
coronary artery disease which cannot be identified by cardiovascular screening. Other causes 
of SCD which may be identified by screening such as familial arrhythmias and 
cardiomyopathies were rare. This study did not include survivors of cardiac arrest and so we 
cannot comment on survival rates following successful defibrillation which may affect the 
numbers of deaths.   
 
Results suggest that a screening model for all in Scotland may not be cost effective and 
instead should be targeted to those at risk due to family history or personal symptoms. Part 2 
of this thesis will evaluate the Cardiac Assessment in Young Athletes (CAYA) programme 
which was established in 2008.  This study is unique in that it includes echocardiography for 
all subjects in addition to the gold standard Italian Model.      
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Chapter 5 - Results Part 2 
Between November 2009 and December 2012, 1955 subjects took part in the Cardiac 
Assessment in Young Athletes programme.  Of these, complete data on those aged 10-35 
years was available on 1713 subjects with the remaining 242 excluded from analysis due to 
technical issues leading to incomplete results.   
 
5.1. Demographic Data 
One thousand seven hundred and thirteen subjects aged between 10-35 years with a mean 
age of 19.8 years were included in this analysis. Subject demographics can be seen in Table 5-
1.  The distribution of ages is represented graphically in Figure 5-1. The majority of subjects 
were male (1429 subjects) with most (87%) being footballers.  Ninety eight percent of 
subjects were white (n=1679). 
 
Table 5-1: Demographic data from 1713 subjects from Cardiac Assessment in 
Young Athletes (CAYA) programme 
 Total Males Females 
Numbers 1713 1429 284 
Mean Age 19.8 (±4.6) years 19.8 (±4.4) years 19.6 (±5.5) years 
Mean Height 174.8 (±9.1) cm 176.7 (±8.4) cm 165.6 (±6.5) cm 
Mean Weight 69.3 (±11.7)kg 70.8 (±11.4) kg 62.0 (±10.1) kg 
Mean Body Surface 
Area 
1.83 (±0.2) 1.86 (±0.2) 1.68 (±0.2) 
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Figure 5-1: Histogram showing distribution of age of all subjects 
 
The 1713 subjects were then split into 5 age category groups for further analysis of these 
mean values.  The number of subjects in each category can be seen in Figure 5-2, with the 
majority being 15-19 years old (63%). 
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Figure 5-2: 1713 subjects of the CAYA programme separated into age categories 
for further analysis  
 
 
5.2. Personal and Family History  
Subjects were asked to complete the personal and family history questionnaire (Appendix A) 
in advance of their appointment, and were then questioned on any positive responses to 
gain more information.  The numbers of positive responses can be seen in Table 5-2. 
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Table 5-2: Results of the personal history and family history questionnaire based 
on the Lausanne Recommendations 
PERSONAL HISTORY N % 
Have you ever been told that you have a heart condition?    14 0.8 
Have you ever had chest tightness at rest/exertion? 115 6.7 
Have you ever fainted during exercise? 22 1.3 
Have you ever been told you have asthma? 307 17.9 
Have you ever been told you have raised/high blood pressure? 23 1.3 
Have you ever been told to give up sports because of a health problem? 
 
3 0.2 
Have you ever been diagnosed with a heart murmur? 35 2.0 
Have you ever experienced irregular heart beat (palpitations)? 56 3.3 
Do you become breathless/tired far more quickly than your team mates? 35 2.0 
Have you ever felt dizzy/faint after exercise/exertion? 106 6.2 
Have you ever had a seizure or been diagnosed with epilepsy? 
 
13 0.8 
Have you routinely taken medication in the past two years? 74 4.3 
 
                              
Has anyone in your family: N % 
Died suddenly or unexpectedly?  178 10.4 
Been treated for recurrent fainting? 9 0.5 
Had unexplained seizure problems? 9 0.5 
Had an unexplained drowning whilst swimming? 0 0 
Had an unexplained car accident? 5 0.3 
Had heart surgery? 205 12.0 
Had a pacemaker implanted? 65 3.8 
Had a defibrillator implanted? 1 0.05 
Been treated for an irregular heartbeat? 72 4.2 
Has anyone in your family been told they have vascular disease? 10 0.6 
Has anyone in your family been told they have Marfan Syndrome? 0 0 
 
The largest positive response on the personal medical history was those suffering from 
asthma (17.9%) although a large number of this group were asymptomatic and did not take 
medication.  Those who answered positively for medication use were for asthma or skin 
problems such as acne.  Those who had been told they had a heart condition were found to 
be murmurs diagnosed at birth which had given no further health problems. 
 
Of the subjects who had been told to give up sport (n=3), none of these were due to cardiac 
problems and all had resumed sport following a period of illness with appropriate medical 
advice. 
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5.3. Physical Examination 
112 subjects had a murmur heard on auscultation (6.5%), this included 24 who had 
previously been told they had a heart murmur.  No subjects presented with physical 
characteristics of Marfan syndrome and none of them had a diminished femoral pulse.   
 
5.3.1. Blood Pressure 
The mean blood pressures recorded were 129.3mmHg systolic and 75.0mmHg diastolic.  
They were then categorised by age in Table 5-3.  Mean values can be seen to increase with 
age (Table 5-3).  
 
Table 5-3: Mean systolic and diastolic blood pressure values according to age 
category 
 10-14 years 15-19 years 20-24 years 25-29 years 30-35 years 
Mean Systolic 
(±SD) mmHg 122.3 (±14.7) 128.5 (±12.2) 131.1 (±13.5) 131.0 (±13.5) 133.2 (± 12.8) 
Mean 
Diastolic 
(±SD) mmHg 72.7 (±9.7) 74.1 (±9.9) 75.5 (±9.4) 77.4 (±9.8) 80.1 (± 7.8) 
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The box plot illustrated in Figure 5-3 and 5-4 show an increase in both systolic (Figure 5-3) 
and diastolic (Figure 5-4) blood pressure with increasing age category but with no significant 
differences found.  
 
 
Figure 5-3: Boxplot illustrating relationship between age and systolic blood 
pressure 
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Figure 5-4: Boxplot illustrating relationship between age and diastolic blood 
pressure  
 
Spearman rank correlation coefficient was r=0.125 suggesting a weak correlation but this was 
statistically significant (p<0.0001).  Linear regression suggests that age category is a 
significant predictor of blood pressure (p<0.001) and that systolic BP increases by a factor of 
1.783mmHg for each age category.    
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Blood pressure results were then categorised into 4 groups as per Table 2-5 (in methodology) 
which can be seen in Figure 5-5.   
 
408 (24%)
918 (53%)
339 (20%)
48 (3%)
Normal
Pre Hypertension
Stage I Hypertension
Stage II Hypertension
 
Figure 5-5: Percentages of subjects within each of the blood pressure category  
 
The majority of subjects in our study (318 athletes, 18.6%) with hypertension were found to 
have systolic hypertension (>140mmHg) with only 14 athletes having a diastolic BP greater 
than 100mmHg.   
 
Table 5-3 shows that the majority of subjects with more severe hypertension (Stage 2) are in 
the older age category (30-35 years).  When analysed with age (Figure 5-6) we can see a large 
proportion of ‘normal’ blood pressure in the younger age categories. Stage I hypertension 
appears to be common in all age groups, with a fairly broad rise in higher BP (Stage II 
hypertension) in those aged 30-35 years.   
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Figure 5-6: Distribution of BP across age category shown as percentages of each 
BP code 
 
We investigated whether blood pressure could be correlated with age but the correlation 
coefficients remained low (systolic v age r=0.142, diastolic v age r=0.176) although 
statistically significant (p<0.001). 
 
Figure 5-7 illustrates the relationship between BSA and BP category.  When comparing body 
surface area (BSA) with BP, there is a small trend of higher blood pressure with increased 
BSA.  The Pearson correlation coefficient is 0.344 when comparing BSA and systolic BP 
(p<0.001) but is not as strong for diastolic BP (r=0.066 and p=0.006). A Spearman Rank 
correlation was carried out to assess the relationship between BSA and BP code and this 
found r=0.302 (p<0.001).  
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Figure 5-7: Boxplot examining the relationship between body surface area (BSA) 
and BP category 
 
5.3.1.1. Blood Pressure Sub-study 
Thirty five male Caucasian footballers were identified and invited to participate in this sub-
study (17 in study group with stage I or stage II hypertension, 18 as control).  The mean 
systolic BP in the hypertensive footballers was significantly reduced from 148.6mmHg to 
130.2mmHg (p<0.001) with mean diastolic being significantly reduced from 83.4mmHg to 
79.7mmHg (p=0.007). Control readings did not alter (p>0.05). These initial results suggest 
that the original high blood pressure recordings have been caused by anxiety and/or other 
stress as home BP monitoring has provided normal or pre-hypertensive readings for all 
subjects (Table 5-4).   
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Table 5-4: Initial BP results with follow up home BP measures for the 17 subjects 
in the BP sub-study 
Initial BP Recording Initial BP Code Average Home BP 
Result 
Follow up BP Code 
150/73 Stage I hypertension 124/68 Pre-hypertensive 
150/72 Stage I hypertension 134/70 Pre-hypertensive 
142/88 Stage I hypertension 126/78 Pre-hypertensive 
141/83 Stage I hypertension 127/81  Pre-hypertensive 
139/93 Stage I hypertension 118/79 Normal 
145/82 Stage I hypertension 132/80 Pre-hypertensive 
154/79 Stage I hypertension 138/86 Pre-hypertensive 
143/80 Stage I hypertension 133/80 Pre-hypertensive 
147/81 Stage I hypertension 136/79 Pre-hypertensive 
139/91 Stage I hypertension 128/84 Pre-hypertensive 
144/77 Stage I hypertension 131/78 Pre-hypertensive 
141/85 Stage I hypertension 127/79 Pre-hypertensive 
142/83 Stage I hypertension 131/81 Pre-hypertensive 
156/89 Stage I hypertension 139/82 Pre-hypertensive 
171/88 Stage II hypertension 124/81 Pre-hypertensive 
162/91 Stage II hypertension 129/86 Pre-hypertensive 
160/82 Stage II hypertension 137/88 Pre-hypertensive 
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5.4. Electrocardiogram (ECG) 
The main clinical finding on ECG was bradycardia with 426 subjects (24.9%) having a heart 
rate lower than 55bpm (mean 62.8 (±11.5) bpm).  The mean QT interval was 402.1ms (±35.7) 
with the mean corrected QT (QTc) being 409.0ms (±24.5).  One hundred and thirty two 
subjects (82 male and 50 female) had a QTc longer than 440ms which was previously 
considered prolonged according to the ESC criteria. Table 5-5 provides the mean values for 
measured intervals as well as providing the numbers of subjects with what would be deemed 
'abnormal' measures according to the Seattle Criteria82.  
 
Table 5-5: Mean ECG values with abnormal values according to the Seattle 
Criteria
82
 
Measure Mean Value (±SD) Abnormal range Number of abnormal 
Heart Rate 62.8bpm (±11.5) <55bpm 426 (24.9%) 
QTc 409.0 (±24.5) Male >470ms      
Female >480ms 
3                                             
3  
PR interval 146.7 (±28.3) <120ms 177 (10.3%) 
Voltage criteria 
(V1+V5) 
33.8 (±10.1) >35mm 700 (40.9%) 
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Of the 1713 ECG’s recorded, only 250 (14.6%) could be considered to have abnormal findings 
according to the Seattle criteria (Table 5-6)82. 
 
Table 5-6: Numbers of abnormal ECG’s in the current study according to the 
Seattle criteria
82
 
Abnormal Finding Numbers in CAYA Study  
T wave inversion 62 (3.6%) 
ST-segment depression 139 (8.1%) 
Pathologic Q waves 0 
Complete LBBB 0 
IV conduction delay 31 (1.8%) 
Left axis deviation 0 
Left atrial enlargement 0 
Right ventricular hypertrophy pattern 7 (0.4%) 
Ventricular pre-excitation 3 (0.2%) 
Long QT interval (>470ms in males or >480ms in 
females) 
6 (0.4%) 
Short QT interval (<320ms) 2 (0.1%) 
Brugada-like ECG pattern 0 
Profound sinus bradycardia 0 
Atrial tachyarrhythmias 0 
Premature ventricular contractions 0 
Ventricular arrhythmias 0 
 
 
Additional ECG findings included 3 subjects with Wolff-Parkinson White syndrome 
(ventricular pre-excitation), only 1 of whom was symptomatic (occasional palpitations and 
dizziness) which would have been identified on questionnaire. One subject was also 
diagnosed with LQTS who had been symptomatic with dizziness.   
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5.4.1. Left Ventricular Hypertrophy on ECG (V1+V5) 
Seven hundred subjects (40.9%) were found to have voltage criteria for LVH on ECG (V1+V5 
>35mm).  There was a very weak but statistically significant correlation (r=0.1, p<0.001) 
between voltage criteria and age as can be seen in Figure 5-8. 
 
 
Figure 5-8: Scatter plot illustrating the relationship between age and left 
ventricular hypertrophy (V1+V5) on ECG (r=0.1, p<0.001) 
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5.5. Echocardiogram 
5.5.1. Left Ventricular Wall Measurements 
The mean left ventricular posterior wall thickness (LVPWd) was 10.1 (±1.6) mm.  Four 
hundred and twelve subjects (24.0%) were found to have a LVPWd greater than 11mm, with 
74 subjects (4.3%) found to have a LVPWd of 13mm or greater.   Figure 5-9 suggests a higher 
percentage of older athletes with increased wall thickness. 
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Figure 5-9: Percentage of age category with left ventricular posterior wall 
thickness (LVPWd) greater than 11 and ≥13mm 
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A very weak but statistically significant correlation was found between left ventricular wall 
thickness and age (r=0.170, p<0.001) which is illustrated in Figure 5-10.  
 
 
Figure 5-10: Scatter plot of left ventricular wall thickness with age (Pearson 
correlation r=0.170, p<0.001) 
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5.5.2. Septal Measurements 
The mean inter-ventricular septal thickness (IVSd) was 10.2 (±1.6) mm.  Four hundred and 
sixty three subjects (27.0%) were found to have a IVSd greater than 11mm, with 87 subjects 
(5.1%) found to have a IVSd of 13mm or greater.   Figure 5-11 shows an increase in the 
number of subjects with septal thickness greater than 11mm per age category. 
 
 
Figure 5-11: Percentage of age category with intra- ventricular septal diameter 
(IVSd) greater than 11 and ≥ 13mm 
 
 
A very weak correlation was found between age and septal thickness (r=0.189, p<0.001) 
showing no direct relationship (Figure 5-12).  
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Figure 5-12: Scatterplot of septal thickness and age (r=0.189, p<0.001) 
 
5.5.3. Relationship between left ventricular wall thickness and septal 
thickness 
Analysis was carried out to establish whether there was a relationship between septal 
thickness and posterior wall thickness which gave us a Pearson correlation coefficient of 
r=0.6 (p<0.001) suggesting a linear relationship which can be seen in Figure 5-13.  The finding 
of a linear relationship between IVSd and LVPWd provides evidence of symmetrical 
hypertrophy in this population which is suggestive of athlete's heart rather than HCM where 
the hypertrophy is normally asymmetrical.  
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Figure 5-13:  Scatter plot of wall thickness v septal thickness showing the Pearson 
correlation coefficient of r= 0.6 (p<0.05) 
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5.5.4. Valvular Function 
Valves were visually assessed using Doppler echocardiogram.  Any regurgitation was noted 
and is recorded in Table 5-7.  
 
Table 5-7: Numbers of subjects with regurgitation at each of the 4 heart valves 
Valve Number of Subjects % 
Pulmonary 238 15.6 
Tricuspid 433 25.3 
Aortic 30 1.8 
Mitral 213 12.4 
 
The majority of the regurgitation above is trivial or mild suggesting it is physiological. 
Previous studies115 have found up to 45% of normals to have mitral regurgitation and up to 
80% to show pulmonary regurgitation.  Only 26 subjects had more serious regurgitation and 
requiring follow up.   
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5.5.5. Additional Diagnosis 
Forty six additional diagnoses were made on echocardiography which would not have been 
identified with ECG alone (Table 5-8).   
 
Table 5-8: Additional diagnoses made with echocardiography which would not be 
identified using the other screening tools 
Diagnosis Number Identified 
Bicuspid Aortic Valve 10 
Suspected Patent Forearm Ovale (PFO) 12 
Mitral Valve Prolapse (MVP) 2 
Atrial Septal Defect (ASD) 2 
Patent Ductus Arteriosus (PDA) 2 
Aneurysmal Septum 4 
Mobile/Prominent Chiari Network 4 
Flattened tricuspid leaflet 1 
Right Ventricular Enlargement 2 
Mobile Inter-Atrial Septum (IAS) 3 
Non-Compaction cardiomyopathy 2 
Coarctation 2 
 
 
 
5.6. Diagnosis of LVH on ECG and Echocardiogram  
According to the Sokolow-Lyon criteria, LVH can be diagnosed on ECG if the sum total of S 
wave in V1+ R wave in V5 is greater than 35mm.  Seven hundred subjects in this study 
(40.6%) were found to have voltage criteria for LVH (V1+V5 >35mm). Voltage criteria was 
correlated with LVPWd with r=0.137 (p<0.05).  This positive but weak relationship can be 
seen in Figure 5-14. 
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Figure 5-14: Scatter plot showing the relationship between LVH diagnosis on ECG 
(V1+V5) and left ventricular wall thickness on echocardiogram (r=0.137, p<0.05) 
 
Voltage criteria was also correlated with septal thickness which again showed a very weak 
but significant correlation r=0.141 (p<0.05).  This is illustrated in the scatter plot in Figure 5-
15 with no obvious relationship apparent.   
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Figure 5-15: Scatter plot showing the relationship between LVH diagnosis on ECG 
(V1+V5) and septal thickness on echocardiogram (r=0.141, p<0.05) 
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5.7. Relationship between Heart Rate and Echo Parameters 
Heart rate was correlated with both septal thickness (r=0.082, p=0.070) and wall thickness 
(r=0.094, p=0.038).  The significant but weak correlation with wall thickness can be seen in 
Figure 5-16. 
 
 
Figure 5-16: Scatter plot of heart rate and left ventricular wall thickness (r=0.094, 
p=0.038) 
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5.8. Sensitivity and Specificity of Screening Tools for LVH 
In order to calculate how sensitive and specific the screening tools used were in diagnosing 
LVH, we used 2x2 contingency tables to calculate the positive predictive value (PPV) and 
negative predictive value (NPV). These were calculated based on echocardiographic cut offs 
of 11mm and 13mm of hypertrophy for septum and left ventricular wall. 
 
Table 5-9 shows the 2x2 contingency table for detecting left ventricular hypertrophy 
(>11mm) using ECG and echocardiogram.  It shows only 189 subjects with hypertrophy of the 
left ventricular wall (LVPWd) would have been identified using Sokolov-Lyon criteria on ECG.  
This gives a sensitivity of 0.49 (95% CI= 0.416-0.502) and specificity of 0.39 (95% CI=0.379-
0.406).  
 
Table 5-9: 2x2 contingency table comparing ECG and echocardiogram in 
identifying subjects with LVH with wall thickness >11mm 
 LVPWd > 11mm LVPWd ≤ 11mm Total 
With V1+V5>35mm 189 511 700 
Without V1+V5 ≤ 
35mm 
223 790 1013 
Total  412 1301 1713 
 
This table then gives us a positive predictive value (PPV) of 27.0% (95% CI=0.245-0.295) and a 
negative predictive value (NPV) of 78.0% (95% CI=0.763-0.797).  This suggests that the ECG is 
not a useful diagnostic test for left ventricular hypertrophy of posterior wall, but that it can 
identify those without LVH.   
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A 2x2 contingency table was then completed for wall thickness greater than 13mm which 
could be suggestive of pathology. Table 5-10 shows a sensitivity of 0.514 (95% CI: 0.398-
0.628) and specificity of 0.596 (95% CI: 0.591-0.601). The PPV is extremely low at 5.4% (95% 
CI: 0.042-0.066) but NPV is extremely high at 96.4% (95% CI: 0.956-0.973).  
 
Table 5-10: 2x2 contingency table comparing ECG and echocardiogram in 
identifying subjects with LVH with wall thickness ≥ 13mm 
 LVPWd ≥13mm LVPWd <13mm Total 
With V1+V5>35mm 38 662 700 
Without V1+V5 ≤ 
35mm 
36 977 1013 
Total 74 1639 1713 
 
The sensitivity and specificity of ECG in identifying septal hypertrophy was also computed 
using 2 x 2 contingency tables.  Table 5-11 shows a sensitivity of 0.47 (95% CI: 0.429-0.508) 
and specificity of 0.61 (95% CI: 0.599-0.628) for septal hypertrophy of greater than 11mm.  
The PPV of the ECG is 31.0% (95% CI: 0.284-0.336) and the NPV is 75.7% (95% CI: 0.739-
0.775). 
Table 5-11: 2x2 contingency table comparing ECG and echocardiogram in 
identifying subjects with LVH with septal thickness >11mm 
 IVSd >11mm IVSd ≤11mm Total 
With V1+V5>35mm 217 483 700 
Without V1+V5 ≤ 
35mm 
246 767 1013 
Total 463 1250 1713 
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The ECG and echo were then evaluated for septal hypertrophy greater than or equal to 
13mm which may be suggestive of underlying pathology. Table 5-12 shows the 2x2 
contingency table which gives a sensitivity of 0.471 (95% CI: 0.367-0.578) and a specificity of 
0.595 (95% CI: 0.589-0.600). The PPV was only 5.9% (95% CI: 0.046-0.072) but the NPV was 
95.5% (95% CI: 0.946-0.964).  
 
Table 5-12: 2x2 contingency table comparing ECG and echocardiogram in 
identifying subjects with LVH with septal thickness ≤13mm 
 IVSd ≥13mm IVSd <13mm Total 
With V1+V5>35mm 41 659 700 
Without V1+V5≤  
35mm 
46 979 1013 
Total 87 1638 1713 
 
 
5.9. Relationship between Hypertension and Left Ventricular Hypertrophy 
Three hundred and eighty seven subjects were identified as being hypertensive (339 with 
stage I hypertension and 48 with stage II hypertension).  Of these 387 subjects, 174 were 
identified as having LVH on the ECG (V1+V5>35mm) with 87 of these also having LVH on echo 
(>11mm) (40 of wall and 47 of septum)   
 
Pearson correlations were carried out to examine whether there was a relationship between 
LVH and BP code but no associations were found (V1V5 r=0.125, wall r=0.158, septum 
r=0.170, p<0.001).  Results from a Pearson correlation showed a significant but weak 
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relationship between LVPWd and diastolic blood pressure (r=0.051, p=0.034) which is 
illustrated in the scatter plot in Figure 5-16. 
 
Figure 5-17: Scatter plot of correlation between LVPWd and diastolic BP 
suggesting a weak but significant relationship (r=0.051, p+0.034) 
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Chapter 6 -Discussion Part 2 
Consensus opinion is that cardiovascular screening should be made available for those 
participating in sport, but debate remains about what form this screening should take, 
whether it should be mandatory or voluntary and to whom it should be offered.  This study is 
the only UK research to date which has provided echocardiography for all subjects in order to 
evaluate whether the Italian Model of family and personal history, physical examination and 
ECG is sufficient in a Scottish population or whether the addition of echocardiography 
reduces the numbers of false positives provided by ECG and provides further useful 
information on the subjects health.   
 
6.1.  Personal and Family History and Physical Examination 
6.1.1. Patient Demographics 
The majority of subjects in the current study were 15-19 years old (n=1083, 63.2%).  Maron 
et al23 suggest that 65% of young athletes who die are of school age (<17 years old) 
suggesting that perhaps screening should take place when subjects are 15-16 years old in 
order to prevent potential SCD.  Previous studies2 23 have shown males to be at higher risk of 
SCD. We screened more male than female athletes but this reflects participation rates 
particularly when the majority of our subjects were footballers.   
 
We did not ask our athletes regarding personal social habits such as smoking which may 
affect their health.  This was because it was felt it may make our athletes feel uncomfortable 
as this information was to be shared with the clubs.   
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6.1.2. Blood Pressure 
Systolic hypertension is more common than diastolic hypertension in our population (318 
athletes v 14 athletes).  This pattern is in keeping with the physiological changes associated 
with athlete’s heart.  These high numbers of hypertensive readings may be reflective of the 
cardiac adaptations to physical training but results may also suggest a number of subjects 
with possible ‘white coat hypertension’.  
 
A number of possible explanations could account for the high BP readings in our study.  
Anxiety is a common problem, particularly when measuring BP in a clinical area.  The recent 
media attention surrounding screening and the potential implications of a positive finding 
may also cause worry.  Previous research59 has suggested a prevalence of the ‘white coat’ 
phenomenon of 4.4% in adolescent athletes.  Following domiciliary BP monitoring this was 
reduced to 0.5% in a cohort of 410 athletes.  The pilot study carried out on a small number of 
our hypertensive subjects does support ambulatory or home monitoring to rule out true 
hypertension.   
 
The significant relationship that we found between BSA and BP could be an important one as 
it could provide a marker for risk stratification in the future.  There is a trend with a 
significant r-value of 0.302 (p<0.001) which suggests that the larger the athlete, the higher 
the blood pressure is likely to be.  This would be similar to the general population whereas 
overweight or obese subjects would tend to have higher BP measurements.   
 
The pilot sub-study suggests that the hypertension seen in this population is mainly 'white 
coat' with all readings being normal or pre-hypertensive on follow up.  This has led to GP's 
and club doctors being asked to follow up subjects with unexplained high blood pressure 
routinely with a copy of results passed on to us for records.  
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The prevalence of high BP in this population is worrying and may reflect on the fitness and 
environment our athletes are in.  Scotland traditionally has a high incidence of inactivity and 
poor social status (smoking and diet) with the Scottish Health Survey estimating that a third 
of young Scots (aged 16-34) are hypertensive. It could be said that although our population 
are participating in sport, they are not as aerobically fit and healthy as counterparts from 
other countries and sports.   
 
6.2. Electrocardiogram 
Debate exists surrounding the use of ECG in cardiac screening due to concerns about its high 
false positive rate and low specificity for the diagnosis of LVH.  Results from the Italian 
screening model suggest that ECG should be included as standard practise in the cardiac 
assessment of athletes2, but that they must be interpreted with caution, whereas America 
have resisted it’s use due to the supposed false positive results116.   
 
The most common ECG finding in this study is sinus bradycardia, which was present in 24.9% 
of our cohort (n=426).  This is accepted as a 'normal' finding in an athletic population with 
the incidence being as high as 60% in previous studies38.  Sixty two subjects (3.6%) were 
found to have T-wave inversion. Although non-specific in our athletes, this finding in V1-V3 
could be consistent with a diagnosis of ARVC. Previously a QT interval above 440ms was 
considered abnormal but recent guidelines82 have seen this be changed to an abnormal value 
greater than 470ms (480ms in females) due to the QTc being based on a HR of 60bpm and 
athletes generally having lower pulses. 
 
Voltage criteria for LVH (V1+V5>35mm) has been shown to be present in approximately 45% 
of male athletes and 10% female athletes80 117.  Figures in our study are very similar to these 
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with 47.2% of males (n=675) and 8.8% females (n=25) being identified as having a voltage 
criteria for LVH using Sokolov-Lyon criteria.   
Early research suggested that false positive rates with ECG could be as high as 40%62 but 
using the new ESC criteria, this was reduced to 11% increasing the specificity of the test. 
Using the Seattle criteria82, only 14.6% of ECG's in this study (n=250) would be considered 
abnormal warranting further investigation.  Previous data66 86 118 suggest that abnormal ECG 
patterns are more common in black athletes but the current study did not have a large 
enough cohort of these subjects for separate analysis.   
 
Studies2 77 have shown that there is large geographical variation in the incidence and causes 
of cardiac death in young people which can be identified by ECG.  Both ARVC and HCM which 
are the leading causes of SCD in Italy and America can be identified by ECG, whereas this is 
not a tool which can identify CAD and so is not so useful in a Scottish population.   
 
6.3. Echocardiogram 
In the current study, 1081 (63.1%) subjects had normal echo findings, 632 (36.9%) had signs 
of physiological LVH and 39 (2.3%) had evidence of potential pathology.  None of the subjects 
in our study were diagnosed with HCM or were disqualified from sport.  Similar results were 
found in the only other study which has included echocardiography for all subjects85.  This 
study categorised echo findings into 3 groups: normal (n=387, 76%), mildly abnormal 
(physiological remodelling) (n=110, 22%) and abnormal (n=11, 2.2%).  Of the 11 subjects who 
were deemed to have ‘abnormal’ echo findings, 3 required sport participation restriction 
including 1 subject with hypertrophic cardiomyopathy.   
 
Physiological LVH is symmetrical in athletes119.  Most of the subjects in our study (n=632) 
demonstrated symmetrical hypertrophy with a statistically significant positive correlation 
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(r=0.6, p<0.05) found between septal and left ventricular wall thickness.  This is more 
suggestive of physiological remodelling as a result of physical training than any underlying 
pathological condition.  Levy et al120 found LVH on echocardiogram to increase with age, as in 
the current study but no strong correlation was found (r=0.170, p<0.001). 
 
The addition of echocardiography to a standard screening programme is unique to CAYA. This 
was routinely introduced to investigate whether it would reduce the number of 'abnormal' 
screenings identified on ECG and prevent further investigation. Unfortunately, 
echocardiogram cannot identify patients with CHD (unless there has been a previous 
coronary event) and so similar to the ECG, it is perhaps not a useful tool for cardiovascular 
screening in Scotland.   
 
The prevalence of HCM in the UK is around 1 in 5004 which would suggest when screening 
over 1700 subjects, at least 3 participants would be identified as having the condition. From 
this, we can deduct that either HCM is not as prevalent in Scotland, or that subjects with this 
condition, self-select out of sport at a younger age. Although the echocardiogram is not able 
to diagnose CHD, it was useful in identifying ‘other’ cardiac abnormalities which could 
become problematic in later life. Many of these conditions were non-specific such as PFO 
and bicuspid aortic valve which have a high incidence in the normal population121.  Other 
conditions such as atrial septal defects and non-compaction cardiomyopathy are more 
serious and require further consultation with a cardiologist.  By identifying these conditions 
and referring subjects into the NHS system, it could be argued that echocardiogram should 
be routinely used in a Scottish population in terms of long-term follow up.   
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6.4. Relationship between Heart Rate and Echo Parameters 
Bradycardia is a common finding in this study with almost a quarter of athletes presenting 
with heart rates less than 55bpm.  There was a weak but significant correlation between HR 
and both wall thickness (r=0.094, p=0.038) and septal thickness (r=0,082, p=0.070).  It could 
be postulated that the lower heart rates associated with this population relate to fitness 
levels and an increased proportion of LVH compared to a normal population.   
 
6.5. Sensitivity and Specificity in Diagnosing Left Ventricular Hypertrophy 
Previous studies85 122 have found echocardiography to have good sensitivity and specificity in 
diagnosing LVH. Our results show that the ECG has a good NPV suggesting it is useful to 
diagnose those without LVH (particularly that greater than 13mm), but a low PPV suggests it 
is not a useful diagnostic tool. The PPV for posterior wall hypertrophy when examining 
physiological LVH (>11mm) is only 19.3% which increases to 31.0% when looking at potential 
pathological hypertrophy (≥13mm).  The NPV also increases from 69.6% to 75.7% suggesting 
the echocardiogram is a much better identifier of posterior wall hypertrophy than the ECG. 
 
When comparing the Sokolov Lyon criteria with septal hypertrophy on echo, the PPV is as 
low as 5.9% for potential pathological LVH (≥13mm) which increases to 31.0% for 
physiological LVH (>11mm).  This means that the ECG alone cannot be used to diagnose 
those with septal hypertrophy but a NPV of 75.7% for >11mm and 95.5% for ≥13mm suggests 
it can be used to distinguish those with a septal thickness within normal range.  These results 
are similar to that of Baggish et al85 who found that adding ECG to personal and family 
history and physical examination increased the sensitivity of screening from 45.5% to 90.9% 
but it also decreased PPV from 15.0% to 10.4% with an increase in false positive results.   
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6.6. Relationship between Hypertension and Left Ventricular Hypertrophy 
The theory of ‘athlete’s heart’ suggests that physical training is associated with both LVH and 
hypertension.  This relationship was previously thought to be due to pressure overload on 
the heart but it is not clear whether LVH is responsible for increased BP or whether increased 
BP causes LVH. In our study, the majority of those with hypertension also have LVH which 
would support the pressure overload theory.  The intensity and frequency of training may 
also have an effect on this relationship but this information was not collected.   
Diastolic BP has been shown to be more closely related to LVPWd which reflects the pressure 
overload theory122.  The correlation between the two in this study was r= 0.051 (p=0.034) 
which although statistically significant is weak.  Studies have shown that athletes with stage II 
hypertension are likely to go on to develop hypertension in later life and so should be 
continually monitored60.  Blood pressure recording is therefore an important component of 
the screening process and should be annually checked. A letter was sent to a subjects GP 
and/or club doctor if a high reading was recorded requesting them to arrange a follow up 
recording but we did not ensure this was done. 
 
6.7. Summary 
The aim of our cardiovascular assessment programme (CAYA) was not to screen for SCD, but 
to provide reassurance that these young people are able to participate in sport and exercise 
without risk. No subjects were disqualified from sport following screening, but the 
introduction of the echocardiogram did identify a number of cardiac abnormalities which 
require follow up. 
 
The main clinical finding identified in this cohort was hypertension (n-318, 18.6%), but a 
follow up pilot study has suggested this may largely be ‘white coat’ hypertension.  According 
to the Seattle Criteria82, only 250 ECG’s would be identified as ‘abnormal’ with one 3 subjects 
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found to have WPW syndrome and 1 with LQTS.  Nearly 41% of subjects demonstrated 
voltage criteria for LVH on ECG (V1+V5 >35mm) weak correlations were found between this 
and LVPWd and IVSd (r=0.137 and r=0.141, p<0.01).   
 
The inclusion of echocardiogram for all subjects allowed for calculations of sensitivity and 
specificity of the ECG which suggested that with a high NPV, the ECG is a useful tool to 
identify those without pathology, but the additional diagnosis found on echocardiogram 
provided a more comprehensive cardiovascular health assessment.   
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Chapter 7 - Conclusions 
Part one of this research identified that most deaths in the young in Scotland were due to 
accidents (27%), self-harm (16%) and cancers (12%).  Cardiac causes were responsible for 
6.4% of deaths in those aged 1-35 years.  Of these cardiac deaths, a third were attributable to 
coronary heart disease with most of them occurring outside of hospital.  This is of concern in 
such a young age group and suggests that cardiovascular screening with ECG and 
echocardiogram may not be useful in reducing the number of cardiac deaths in Scotland 
although due to the inability of these tools to identify CHD. Instead, results suggest that 
better education regarding lifestyle choices to reduce weight, decrease cholesterol, reduce 
alcohol intake, help smoking cessation and increase physical activity could help to decrease 
the prevalence of CHD.   
 
Screening or cardiovascular assessment may still be useful to identify persons at risk of 
cardiac events such as cardiomyopathy or familial arrhythmias and it may also identify other 
health related problems such as hypertension which if not treated could become a health 
problem in the future. From the current study, we cannot comment on whether lives have 
been saved as this would require a longitudinal investigation to follow up our subjects over 
time. 
 
In order for us to be able to accurately calculate the true incidence of SCD in both the general 
population and deaths related to sport, Scotland and the whole of the UK needs a Register of 
all sudden deaths to be established with information regarding the origin of the initial 
collapse and cause of death. In addition to this, the circumstances surrounding each death 
need to be considered when assigning a cause of death with pathologists made more aware 
of SADS.   
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Results of the CAYA programme show the ECG to have a high negative predictive value 
suggesting it to be a useful tool to identify subjects without underlying cardiac pathology. 
Routine echocardiography led to a number of conditions being identified in our population, 
some of which require treatment.  Results suggest that any future screening programme 
should include personal and family history, PE and ECG and should be confined to those who 
are symptomatic, have a family history of heart problems or are undertaking exercise on a 
regular basis.   
 
Scotland traditionally is a nation with high levels of deprivation, smoking and inactivity and 
obesity and associated high blood pressure which are all risk factors for CHD.    This study did 
not set out to examine this disease in the young and would require exercise testing and 
angiography to investigate this fully which would not be cost effective.  
 
 
We believe that a screening programme should be available in Scotland but that this should 
not be mandatory.  Based on the results of Part One of the study which show the highest 
number of deaths due to structural disease such as cardiomyopathy to occur aged 15-19 
years, we believe this programme should target 15-16 year olds.  We would also wish to 
highlight and educate young people in the 4 main symptoms of heart disease that people 
should have further investigation of: chest pain, dyspnoea, syncope and palpitations. In 
addition to cardiovascular screening, we suggest that automatic external defibrillators (AED) 
should be more readily available at sports grounds with coaches and officials trained properly 
in first aid to increase survival rates in the event of a cardiac arrest.   
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Appendix A -
Questionnaire 
 
  
PERSONAL HISTORY YES NO 
Have you ever been told that you have a heart condition?      
Have you ever had chest tightness at rest/exertion?   
Have you ever fainted during exercise?   
Have you ever been told you have asthma?   
Have you ever been told you have raised/high blood pressure?   
Have you ever been told to give up sports because of a health problem? 
 
  
Have you ever been diagnosed with a heart murmur?   
Have you ever experienced irregular heart beat (palpitations)?   
Do you become breathless/tired far more quickly than your team mates?   
Have you ever felt dizzy/faint after exercise/exertion?   
Have you ever had a seizure or been diagnosed with epilepsy? 
 
  
Have you routinely taken medication in the past two years? 
If yes, what? 
 
 
 
  
 
                              
Has anyone in your family: YES NO 
Died suddenly or unexpectedly?    
Been treated for recurrent fainting?   
Had unexplained seizure problems?   
Had an unexplained drowning whilst swimming?   
Had an unexplained car accident?   
Had heart surgery?   
Had a pacemaker implanted?   
Had a defibrillator implanted?   
Been treated for an irregular heartbeat?   
Has anyone in your family been told they have vascular disease?   
Has anyone in your family been told they have Marfan Syndrome?   
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Appendix B – Ethical Approval 
 
Dear Miss Stewart 
Medical Faculty Ethics Committee 
Project Title:  Cardiac Assessment of Young Athletes (CAYA) 
Project No.:  FM04109 
 
The Faculty Ethics Committee has reviewed your application and has agreed that there is no 
objection on ethical grounds to the proposed study now that the requested revisions have 
been incorporated.  They are happy therefore to approve the project, subject to the following 
conditions: 
 
 The research should be carried out only on the sites, and/or with the groups defined in the 
application. 
 Any proposed changes in the protocol should be submitted for reassessment, except 
when it is necessary to change the protocol to eliminate hazard to the subjects or where 
the change involves only the administrative aspects of the project.  The Ethics Committee 
should be informed of any such changes. 
 If the study does not start within three years of the date of this letter, the project should be 
resubmitted. 
 You should submit a short end of study report to the Ethics Committee within 3 months of 
completion. 
 
 
Yours sincerely 
Dr Una MacLeod 
Faculty Ethics Officer 
 
 
 
 
Dr U MacLeod  
Clinical Senior Lecturer  
General Practice & Primary Care, Division of Community  
Based Sciences, University of Glasgow, 1 Horselethill Road, Glasgow, G12 9LX  
Tel: 0141 330 8328   
E-mail: u.macleod@clinmed.gla.ac.uk  
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Appendix C -  Info 
Sheet 
The Cardiac Assessment in Young Athletes (CAYA) screening programme is supported by the Scottish 
Government to perform a series of tests in the young athletes to exclude conditions which may reduce 
sporting performance or lead to serious health risks. 
 
Exercise and sporting activities have been shown to give major improvements to health in general, and 
to promote a healthy heart and circulation. In a few individuals however, exercise can cause problems 
even to the extent of sudden death, if there is an underlying cardiac abnormality. Cardiac screening 
has been shown in Italy to confirm normal cardiac function in most sports participants but it can also to 
be effective in reducing the risks associated with heart disease. 
 
The conditions which should be excluded are heart muscle disease (Cardiomyopathy), structural 
problems of the heart affecting the valves or blood vessels and abnormalities of the electrical system of 
the heart. 
 
The screening consists of: 
 
 A health questionnaire regarding your health and your family’s medical history including 
symptoms such as chest pain, undue breathlessness and an abnormal awareness of your 
heart beat or fainting on exercise which may suggest a problem. 
 
 A medical examination including blood pressure measurements and audible assessment of the 
heart. 
 
 An electrocardiogram (ECG); this records the electrical signal of your heart from the surface 
which gives information concerning the rate, rhythm and electrical function. 
 
 An echocardiogram (ECHO); this gives a 2D picture of the heart which shows the structure and 
shape of the heart muscle and also assesses the valves. 
 
 
 
 
It is important to emphasise that although screening is used to confirm normal cardiac function, 
occasionally cardiac abnormalities may be identified and may lead to advice being given concerning 
future exercise activity, and to recommend further investigations and treatment if advisable. 
 
A report of your test results will be sent to your doctor in confidence. If further tests are indicated, 
contact with you permission, will be made with a local specialist. 
 
In rare cases there may be implications regarding employment and insurance issues. 
 
It is important that you read this background document and understand all the potential 
outcomes and implications before you undergo screening. 
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Appendix D – 
Consent Form  
  
 
Thank you for volunteering to take part in the CAYA programme. Please read the 
attached information sheet in order that you will be aware of the potential outcomes if 
any of the tests show an abnormality of your heart. Screening programmes, such as 
these, have been shown to reduce the incidence of cardiac complications including 
the risk of sudden death during activity. Please remember these conditions are rare 
but like any screening programme, these tests are designed to pick up conditions 
before symptoms occur. The screening programme is of course voluntary and we will 
pass the information gained to your GP only with your permission. 
 
 
 
 
I,   ................................................... (name) of  ..............................................................  
(address) give informed consent to have heart screening carried out and that I have read and 
understood the cardiac screening fact sheet. I also give my consent for the information to be 
passed to my GP and/or Club Doctor in medical confidence. 
 
 
 
Signed   ................................................  
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Appendix E –BP Sub-Study 
Thank you for volunteering to take part in the CAYA programme. You have previously 
been provided with an information sheet regarding the potential outcomes if any of 
the tests show an abnormality of your heart. Screening programmes such as these, 
have been shown to reduce the incidence of cardiac complications including the risk 
of sudden death during activity. Please remember these conditions are rare but like 
any screening programme, these tests are designed to pick up conditions before 
symptoms occur.  
As part of the CAYA programme you will recall your blood pressure was checked. 
Analysis of the footballers screened has shown many players have slightly elevated 
blood pressure. For research purposes a number of these players have been 
identified to be re-tested. A similar number who had normal blood pressure will also 
be re-tested for comparison. 
Please read the attached information sheet regarding what further testing will be 
undertaken and sign below if you agree to take part. 
 I,  ................................................... (name) of   
........................................................................................................................(address)  
give informed consent to have blood pressure screening carried out and that I have 
read and understood the information sheet. I also give my consent for the information 
to be passed to my GP in medical confidence if necessary. 
 
Signed  ................................................ (Parent/guardian if under 16 years).  
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Information Sheet  
 The CAYA (Cardiac Assessment of Young Athletes) programme has been screening 
professional footballers in Scotland for cardiac abnormalities since 2008. This is a 
joint venture between the Scottish Government, the Scottish Football Association and 
the University of Glasgow.  At your initial screening you will have been provided with 
an information sheet regarding the potential outcomes if any of the tests show an 
abnormality of your heart. Screening programmes such as these, have been shown to 
reduce the incidence of cardiac complications including the risk of sudden death 
during activity. Please remember these conditions are rare but like any screening 
programme, these tests are designed to pick up conditions before symptoms occur.  
 
As part of the CAYA programme you will recall your blood pressure was checked. 
Analysis of the footballers screened has shown many players have slightly elevated 
blood pressure. For research purposes a number of these players have been 
identified to be re-tested. A similar number who had normal blood pressure will also 
be re-tested for comparison. 
 
Taking part in this research is voluntary and the CAYA team thank you for your 
support. Previous research has shown that blood pressure is often artificially high 
when taken by a doctor or at a screening facility. As a result it has been arranged for 
each player identified to be given an electrical blood pressure monitor to take home 
for 4 days each. 
In keeping with recent guidance from the National Institute of Clinical Excellence 
(NICE): 
- Each player should take a blood pressure twice in the morning and twice in 
the evening.  
- This should be taken from the right arm while sitting, relaxed at rest.  
- Please record all of the measurements on the diary provided and hand this 
back with the monitor to your club physio. 
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